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SUMMARY 
Metallothioneins (MTs) are unusual, cysteine rich proteins, which can 
sequester heavy metals (including zinc and cadmium), and also have free radical 
scavenging properties, which allow them to protect cells from cytotoxicity 
induced by reactive oxygen species. In the last 10 years, interest in the potential 
roles of these proteins has shifted from metal homeostasis and free radical 
scavenging to the neurological functions which they may possess. In this regard, 
it is the brain specific, MT-III isoform, which has been of most interest. This 
protein exhibits neuronal growth inhibitory properties upon cultured cortical 
neurons, and also has been proposed to be involved in the development of 
Alzheimer's disease. The aim of this thesis is to further investigate the proposed 
neuroactive properties of MTs, at both a functional and biological level, to 
determine their possible role within the brain. 
This study firstly investigated the relationship between structure and 
• biological function of MT-III by investigating the neuronal growth inhibitory 
activity of a variant MT-III protein previously identified in this laboratory, 
namely sheep MT-III. This protein was produced recombinantly, and by 
comparison with recombinant human MT-III, reductions in its metal binding and 
neuronal growth inhibitory activity upon cultured cortical rat neurons were found. 
These results indicate the importance of protein structure to MT-III's inhibitory 
activity, and may also partly explain the susceptibility of sheep to heavy metal 
induced toxicity. 
MT-III has. also been proposed to inhibit neurite outgrowth, although all 
available studies in the literature have alternatively focused upon its ability to 
inhibit neuronal survival. Using recombinant human MT-III, this study found that 
MT-III does indeed inhibit initial neurite formation and growth when applied to 
cultured cortical rat neurons. Furthermore, following axonal transection in 
culture, MT-III inhibited reactive (or regenerative) neurite sprouting. These 
results support the hypothesis in the literature that reduced levels of MT-III in the 
brain allow the aberrant neurite sprouting observed in Alzheimer's disease. 
Rather surprisingly, it was found that another MT isoform, human MT-
IA, promoted neurite elongation, reactive sprouting, and growth following injury 
in the same culture models. At the same time, several reports in the literature 
demonstrated that MT-I and —II knockout mice had significantly reduced cortical 
wound healing capacity and that exogenous application of MT-II promoted 
cortical wound healing. To elucidate whether the neuroactive properties observed 
in culture within this study were involved in this response, human MT-IA was 
applied following focal cortical brain injury in the adult rat. MT-IIA promoted 
marked neural recovery following injury, suggesting that MT-I and MT-II might 
act in an extracellular capacity to promote cortical wound healing, as well as their 
better investigated intracellular roles. 
Based upon the demonstration, both within the literature and this thesis, 
that MTs can modulate neural recovery following injury, it was hypothesized that 
these properties might relate to their physiological function within the brain. In 
this regard, this hypothesis would explain the observation within the literature that 
MT-I and —II are up-regulated within astrocytes in response to various forms of 
brain injury and neurodegenerative disorders. Using neuron/astrocyte co-cultures, 
this study found a similar pattern of MT-I and —II up-regulation following scratch 
wound injury. However, injury to pure astrocyte cultures did not result in 
changes in MT-I and —II expression, suggesting that MT-I and —II respond 
specifically to neuronal injury. Based upon these results, .this thesis proposes a 
potential model/hypothesis for MT action within the CNS, where they are up-
regulated in astrocytes in response to neuronal injury, released, and subsequently 
promote/inhibit neuronal recovery. 
In summary, this thesis presents data suggesting an important role for 
extracellular MTs in the cellular response to neuronal injury. Furthermore, the 
neuroactive properties of MTs discovered in this work reveal the possibility of 
metallothionein based therapeutics in the context of brain injury. 
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BSA 	bovine serum albumin 
CNS 	central nervous system 
DTT 	dithiothreitol 
EAE 	experimental autoimmune encephalomyelitis 
EDTA 	ethylene diamine tetra-acetic acid 
FCS 	fetal calf serum 
GFAP 	glial fibrillary acidic protein 
HEPES 	N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) 
IPTG 	isopropyl-p-D-thiogalactopyranoside 
LDS 	lithium dodecyl sulphate 
MES 	2-(N-morpholino) ethane sulfonic acid 
MT . 	metallothionein 
MW 	molecular weight 
PBS 	phosphate buffered saline 
PI 	post-injury 
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
Tris 	tris(hydroxymethyl)aminomethane 
ix 
MT NOMENCLATURE 
Despite the recommendations made by the Committee on the 
Nomenclature of Metallothionein appointed at the General Discussion Session of 
the Second International Meeting on Metallothionein and Other Low Molecular 
Weight Metal-binding Proteins (see Fowler et a/, 1987), MT nomenclature has 
not been standardised. 
This thesis discusses primarily MT proteins from human, although a 
variety of other mammalian MTs may be briefly mentioned. The distinction 
between these different mammalian isoforms is important to note, and has been 
made throughout the text. 
The MT family of proteins consists of 4 primary isoforms, referred to as 
MT-I, MT-II, MT-III and MT-IV. However, each isometallothionein family 
consists of a number of specific subforms. Human MT subforms are designated 
following the guidelines for human gene nomenclature established by Karin et al 
(1984) and West et al (1990), i.e. human MT-IA. 
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Embryonic rat cortical neurons were cultured at high cell density, promoting the 
formation of neuronal clusters. By 21 days in vitro, fasciculated axonal bundles 
formed between clusters, which were transected by microscalpel. By 12 hours 
post-injury, several reactive axonal sprouts were observed by fluorescent 
immunocytochemistry entering the injury site (green — rIIII-tubulin; red — tau). 
However, treatment with recombinant human MT-III significantly inhibited 
reactive sprouting. This figure appeared on the cover of Experimental Neurology 
(Issue 178, 2002). 
Chapter 1 — Introduction 
This introduction will provide a brief overview of the development of the 
mammalian brain, followed by a summary of the response of the mature CNS to 
injury. Continuing this theme, an overview of our current knowledge of the 
metallothionein family of proteins will be presented, based on the recent 
demonstration that these proteins are intimately involved in the cellular response to 
brain injury as well as in the pathogenesis of a number of neurodegenerative 
disorders. 
1.1 Development of the neuronal architecture of the brain 
The development of the mammalian brain involves the complex interplay of a 
number of different processes. These include initial neurite formation and outgrowth 
(a neurite being any process extending from the cell body, including both axons and 
dendrites), neurite guidance and growth, and finally synapse formation. Following is 
a brief overview of these processes. 
1.1.1 Initial neurite formation, outgrowth and elongation 
The initial processes involved in neurite formation have been well 
characterized (see Tanaka & Sabry, 1995; Tessier-Lavigne & Goodman, 1996; 
Brandt, 1998). The first step is the formation and outgrowth of multiple, 
morphologically indistinguishable minor neurites, one of which becomes an axon 
with a growth cone. 
The growth cones are highly motile, hand-like structures which are 
responsible for the directed growth of the neurite the long distances required for it to 
reach its correct target. They sample the external environment, and respond to 
numerous molecular stimuli to guide neurite growth. Guidance cues can be positive 
(attractive) or negative (repulsive), and the correct reading and integration of these 
cues by the growth cone is essential for the precise wiring of the brain (as reviewed 
by Mueller, 1999). 
Underlying the outgrowth of neurites from the cell body are changes in the 
dynamic cytoskeleton of the neuron. The major components of the neuronal 
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cytoskeleton are filamentous actin (F-actin), which is the primary component of the 
peripheral domain of the growth cone, and microtubules, of which the neurite shaft, 
and the central domain of the growth cone are composed (Figure 1.1). 
Neurite growth relies upon dynamic microtubules and actin. Initially the 
filopodia advance by the assembly of new actin filaments at the leading edge of the 
growth cone, followed by the flow of microtubules from the central core into the 
newly extended protrusion, leaving behind a new stretch of axon (Figure 1.2). 
1.1.2 Synapse formation 
When axons reach their appropriate targets they form synapses, structures 
which permit signaling between neurons. Synapse formation involves three key 
events: the formation of selective connections between the developing axon and its 
target, the differentiation of the growth cone into a nerve terminal, and the 
elaboration of the postsynaptic terminal in the target cell. This process is driven by 
bi-directional, intercellular interactions that allow the recognition of the appropriate 
postsynaptic cell followed by the coordinated differentiation of pre- and post-
synaptic elements of the synapse. These steps are briefly described in Figure 1.3, 
using the example of the well characterized neuromuscular junction, the synapse 
formed between motor neurons and skeletal muscle fibres. 
1.2 The neuronal response to injury 
Within mature central nervous system neurons, injury to the cell body will 
often lead to neuronal death. However, damage to the axon results in the neuron 
exhibiting a characteristic response to injury. Initially this involves two processes, 
Wallerian degeneration and chromatolysis. 
1.2.1 Wallerian degeneration and chromatolysis 
Transection of the axon (axotomy) results in a division of the axon into a 
proximal segment (which remains attached to the cell body) and a distal segment. 
The distal segment physically degenerates over a period of time, together with the 
myelin sheath encasing the axon. Axonal debris is removed by phagocytic 
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Figure 1.1: The axonal shaft is composed primarily of microtubules, which also 
extend into the proximal portion of the growth cone. Actin is highly concentrated 
within the filopodia and leading edge of the growth cone. Within filopodia, actin 
fibrils are orientated with their growing tips pointed distally. Within the lamellae, 
actin fibrils are randomly orientated and form a dense meshwork. Modified from Lin 
eta! (1994). 
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Figure 1.2: Neurite growth is driven by dynamic actin and microtubules. The 
filopodia respond to adhesive cues by contracting, which pulls the growth cone 
forward (A). Actin filaments assemble at the leading edge of the filopodia, while 
disassembling at the trailing edge. The force generated by this flow of actin pushes 
the filopodia forward (A 1 ). Membrane is added to the leading edge of the filopodia 
by exocytosis (A2). Actin polymerization pushes the filopodia forward. Actin 
polymers are linked to adhesion molecules on the plasma membrane to provide 
traction (A 3 ). These combined actions result in an actin-poor space that is filled by 
advancing microtubules (B). The microtubules form a new bundle, and the 
cytoplasm collapses around them to form a new length of axonal shaft Modified 
from Heidemann (1996). 
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Figure 1.3: At the mature neuromuscular junction (A), the synaptic cleft separates 
pre- and post- synaptic membranes. Synaptic vesicles are clustered at the pre-
synaptic release site, while transmitter receptors are clustered at the post-synaptic 
membrane. The entire nerve terminal is ensheathed by glial processes. The 
neuromuscular junction forms in a number of discreet steps (B), which begins with 
the growth cone approaching the muscle fibre (1), forming a functional but 
morphologically unspecialized connection (2). The terminal accumulates synaptic 
vesicles, and a basal lamina forms in the synaptic cleft (3). Multiple axons converge 
on a single site (4), but all are eliminated except one that matures to form a functional 
synapse (5). Based on Hall & Sanes (1993). 
microglia/macrophages, and this entire process is termed Wallerian degeneration 
(Figure 1.4). 
In many cases, the proximal segment of the axon and the cell body itself die 
by apoptosis, due to the lack of target derived trophic factors. When this doesn't 
occur, the cell body undergoes a series of changes termed chromatolysis. The cell 
body swells, the nucleus moves to an eccentric position, and the rough endoplasmic 
reticulum fragments (Figure 1.5). Metabolically the cell also changes, by increasing 
protein and RNA synthesis, as well as the pattern of genes expressed. This process is 
often viewed as an attempt by the neuron to regenerate, by regrowing the injured 
axon and re-forming its connections (Deller and Frotscher, 1997; Christman et al., 
1997; Pastor et al., 2000). Axonal growth from the proximal stump is termed 
reactive sprouting, or reactive axonal sprouting (Figure 1.5). 
1.2.2 Reactive axonal sprouting 
It was Ramon _ Cajal (1928) who first proposed that mature injured CNS 
neurons are not capable of regeneration. However, more recently, it has been 
demonstrated that these neurons are indeed able to produce reactive sprouts and 
regenerate if provided with suitable conditions. Such experiments include those 
performed by Aguayo and colleagues (David & Aguayo, 1981; Duncan et al, 1981) 
who implanted peripheral nerve tissue grafts into lesioned spinal cords, and identified 
a number of reactive axonal processes entering the graft. In more recent times, 
inhibitory molecules such as myelin associated glycoproteins and Nogo have been 
identified which inhibit axonal regeneration following injury (see reviews by 
Fournier et al, 2002; McKerracher & Winton, 2002). These experiments suggest that 
reactive axonal sprouting is an intrinsic property of neurons, and experiments in 
culture support this hypothesis. In this regard, it has been demonstrated that injured 
axons of mature neurons are capable of undergoing a defined series of reactive 
changes, ultimately culminating in a sprouting response, which occurs independently 
of the presence or effects of glial cell populations (Dickson et al, 2000; Chuckowree 
& Vickers, 2003). 
'3 
Macrophage Macrophage 
Axotomy — 
Oligodendrocyte Capillary Axonal and 	Oligodendrocyte 
myelin debris 
Oligodendrocyte 
axonal and 
myelin debris 
Figure 1.4: Following injury to the axon (A), the axon undergoes Wallerian 
degeneration. Macrophages migrate into the injury site from the periphery (B), and 
the distal segment of the damaged axon relative to the original injury site degenerates 
over time. Degraded axonal and myelin fragments are removed by phagocytic 
macrophage (C, D). Modified from Jacobsen (1991). 
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Figure 1.5: Following axotomy (B), the neuronal cell body undergoes a series of 
changes collectively known as chromatolysis. The cell body swells, the nucleus 
moves to an eccentric position, and the rough endoplasmic reticulum becomes 
fragmented (B). Metabolic changes follow, including overall increases in RNA and 
protein synthesis of a number of regeneration associated genes (such as GAP-43), 
resulting in a reactive sprouting response (C). Modified from Burt (1993). 
The mechanisms underlying reactive axonal sprouting and growth following 
injury to mature CNS neurons are currently unknown. In this context, it is also 
unclear whether reactive axonal growth recapitulates the same processes and 
mechanisms involved in axonal development, although several experiments suggest 
this. For instance, changes in the expression of a number of cytoskeletal elements (of 
which GAP-43 is the best characterized) reflects those observed during the sequence 
of developmental events which occur during neurite formation and growth (Hoffman 
and Cleveland, 1988; Lee and Cleveland, 1996). Furthermore, following injury to 
mature axons in embryonic rat cortical neuron cultures, growth cone like structures 
have been observed at the distal tips of reactive axonal sprouts (Chuckowree & 
Vickers, 2003). A number of neurotrophic factors, such as the neurotrophin family 
of proteins, which promote developing axonal growth, have also been demonstrated 
to promote reactive axonal growth following CNS injury (see review by Blesch & 
Tuszynski, 2002). 
1.3 The cellular response to brain injury 
Injury to the brain results in the initiation of a number of repair processes. 
These include not only direct neuronal responses (as discussed previously), but also 
changes in the cellular environment of the brain.. In this regard, the role of glial cells 
such as microglia/macrophages and astrocytes are crucial to the brain's response to 
injury. Their response is characterized by the formation of a dense web of interlacing 
glial processes that form within the lesioned area. 
1.3.1 Microglia/macrophage activation in response to brain injury 
As discussed previously, the neuronal response to injury involves degradation 
of axonal components and the myelin sheath. The resultant axonal debris is removed 
by phagocytic microglia that are resident within the CNS, and macrophages which 
migrate into the area of degeneration from outside of the nervous system. These cells 
respond vigorously to traumatic injury with marked hypertrophy, proliferation, 
migration and transition to a different morphological phenotype, dubbed "reactive". 
Reactive microglia/macrophages also exhibit strong secretory properties within the 
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injury environment, producing a variety of molecules which alter the injury 
environment, including cytokines, degradative enzymes (such as proteases) and small 
molecules such as leukotrienes and superoxide (for review, see Banati et al, 1993; 
Streit et al, 1999). 
1.3.2 Astrocytic response to brain injury 
Astrocytes also acquire distinct reactive changes, evidenced both 
morphologically and functionally (as reviewed by Ridet et al, 1997). This process is 
known as astrogliosis and the astrocytes are considered "reactive". This process is 
crucial to the brain's response to neuronal injury, as reports utilising both chemical 
treatments (Bush et al, 1999) and transgenic null-mice (such as IL-6 null mice; 
Penkowa et al, 2000), which result in reduced astrogliosis, exhibit dramatically 
reduced recovery following brain injury. Reactive astrocytes express a number of 
factors that modulate the external injury environment, including cytokines and 
growth factors. Recently, it Has been demonstrated that astrocytes significantly up-
regulate metallothioneins in response to injury, and that these proteins are major 
neuroprotective proteins within the brain (Campagne et al, 1999; Penkowa et al, 
1999a; Trendelenburg et al, 2002). Following is a brief discussion of the 
metallothioneins. 
1.4 The metallothioneins 
1.4.1 General discussion 
The mammalian metallothionein (MT) family of proteins consists of cysteine 
rich (25-30%), low molecular weight (6-7 kDa), heavy metal binding proteins 
(Hamer, 1986; Kagi and Schaffer, 1988; Vasak and Hasler, 2000). There are four 
isoforms; -I and -II (found in most tissues including the brain), -III (brain specific) 
and -IV (found in squamous epithelial tissue) (Palmiter et al, 1992; Quaife et al, 
1994). Throughout this thesis, MT-I and -II will be considered as a single isoform 
denoted MT-I/-II, in light of the fact that they exhibit very high structural homology 
(for instance, >98% in the case of human MT-I and MT-II), and their genes are co- 
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ordinately expressed and respond in parallel to all MT inducers (Yagle & Palmiter, 
1985). 
Much of our current understanding of the functional roles of MTs is based 
upon the comparative analysis of their chemical and structural features. Most 
intriguing is the fact that the structure of all MTs identified so far, including both 
mammalian and non-mammalian (such as crustaceous and bacterial), indicate a 
common monomeric protein structure composed of two globular domains, each 
composed of a metal-thiolate cluster (Figure 1.6). Furthermore, most non-
mammalian MTs generally contain the same number of metal-chelating Cys-Cys and 
Cys-X-Cys motifs (where X stands for any amino acid other than cysteine) as their 
mammalian counterparts. This indicates a tight evolutionary constraint of the key 
structural features of MTs, and suggests the conservation of physiological function. 
In this regard, their heavy metal binding properties allow them to sequester heavy 
metals and protect against metal toxicity (in particular cadmium), and it has been 
suggested that they are able to regulate the availability of metal ions, particularly Zn 
(II) and Cu (I), to various enzymes and transcription factors (Kelly et al, 1996; 
Aschner, 1997). They also have free radical scavenging properties, which allow 
them to protect cells from cytotoxicity induced by reactive oxygen species (Sato and 
Bremner, 1993). 
The discovery of MT-III, a brain specific MT isoform, and the report of its 
down-regulation in Alzheimer's disease (AD), shed light upon the role MTs may play 
within the brain (Uchida et al, 1991). Furthermore, investigation of this isoform 
indicated that different MT isoforms apparently have different roles within the brain. 
Following is a brief discussion of the neurologically important MTs (MT-I, -II and - 
III), and their potential roles within the CNS following injury and in the pathogenesis 
of a number of neurodegenerative diseases. 
1.4.2 Structural differences between MT-I/-II and MT-III 
As discussed previously, all mammalian MTs are monomeric proteins 
composed of two globular domains, each encompassing a metal-thiolate cluster. 
Furthermore, MT-I/-II and MT-III contain the same number of cysteine residues, 
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Figure 1.6: Mammalian metallothioneins are composed of two domains that bind 7 
divalent transition metals such as cadmium (green spheres) and zinc (purple spheres). 
Under natural conditions, it is bound primarily to zinc, and some monovalent copper. 
Figure courtesy of Dr John Beattie. 
found as Cys-Cys and Cys-X-Cys motifs (where X stands for any amino acid other 
than cysteine). However, MT-III has two regions which distinguish it from all MT-
I/-II isoforms. These are a C(6)PCP motif within the i3-domain, and an acidic 
hexapeptide within the a-domain (Figure 1.7). Interestingly, recent NMR studies 
have identified dynamic processes within the metal-thiolate clusters of MT-III, which 
have not been observed in MT-I/-II (Faller et al, 1999). Hence, changes in the 
primary structure of MT-III, when compared with MT-I/-II, result in markedly 
increased structural flexibility, and may result in variations in the biological activity 
of MT-III in comparison to MT-I/-II. As an indication of this, the acidic insertion 
within the a-domain is accommodated in a loop that exhibits structural dynamics, 
and as such is proposed as a possible interaction site with other proteins (Oz et al, 
2001). 
1.4.3 Expression of MTs within the brain 
Within the brain, MT-I/-II comprise approximately two thirds of total brain 
MT (Erickson et al, 1994). The primary cellular source of MT-I/-II within the 
mammalian brain is astrocytes (Nakajima et al, 1991; Nishimura et al, 1992), with 
low levels found in some neuronal populations, and particularly the neurons of the 
CA3 field of the hippocampus (Masters et al, 1994). Glial localized MT-I/-II is 
found within a limited number of CNS regions, including cortex, hippocampus, 
brainstem and spinal cord (Choudhuri eta!, 1995). 
In contrast to MT-I/-II, the cellular localisation of MT-III within the 
mammalian brain is currently unclear. Studies indicate the presence of MT-III at 
both the transcript and protein level in astrocytes only (Uchida eta!, 1991; Nakajima 
& Suzuki, 1995), neurons only (Choudhuri eta!, 1995; Masters eta!, 1994) or in both 
astrocytes and neurons (Yamada et al, 1996; Yuguchi et al, 1997; Zheng et al, 1995). 
Despite these conflicting results concerning the cellular localisation of MT-III, the 
general consensus at present is that like MT-I/-II, MT-III is expressed primarily in 
astrocytes, With low levels (but significantly more than MT-I/-II) in specific subsets 
of 'neurons (Uchida et al, 2002). In regards to regional distribution, MT-III is 
expressed within many of the same CNS regions as including cortex, 
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Figure 1.7: Comparison of the amino acid structure of human MT-HA (the major 
human MT-I/-II representative) and human MT-III (the only human MT-III 
representative). The two major structural differences between MT-I/-II and MT-III 
isoforms, the C(6)PCP motif and acidic hexapeptide insertion, are indicated by boxes. 
Conserved amino acids between the two proteins are indicated by grey shading. 
Dashes in the MT-HA sequence are for alignment purposes. 
brainstem and spinal cord (Choudhuri et al, 1995). However, MT-III is most 
abundant within the granule cells of the dentate gyrus in the hippocampus and 
particularly those neurons that store zinc in their synaptic vesicles (Choudhuri et al, 
1993; Masters et al, 1994). 
1.4.4 MTs and brain injury 
Expression of MT-I/-II is up-regulated in response to a number of 
experimental models of brain injury (as reviewed by Hidalgo et al, 2001). This 
would suggest that MT-I/-II have an important role in the brain's response to injury. 
Indeed, Penkowa and colleagues (1999a) recently demonstrated that MT-I/-II 
transgenic knockout mice exhibit markedly reduced wound healing ability following 
cortical cryolesion. This was followed by a similar report indicating that transgenic 
MT-I/-II over-expressing mice recover much more rapidly than their wild-type 
littermates following focal cortical ischaemia (Campagne et al, 1999). 
While there is significant evidence in the literature to suggest that MT-I/-II 
may promote wound healing within the CNS by protecting tissue from oxidative 
damage or extracellular zinc (for review, see Hidalgo et al, 2001), Penkowa and 
colleagues have recently demonstrated that MT-I/-II knockout mice exhibit dramatic 
changes in inflammatory responses following brain injury (Penkowa et al, 1999b). 
Intriguingly, they have further demonstrated that intraperitoneal application of MT-
I/-II resulted in alterations in inflammatory mechanisms including cytokine activation 
and reactive gliosis, leading to significantly improved recovery following cortical 
brain injury (Penkowa et al, 2002). This suggests that MT-I/-II may not only act 
within the cell to protect against oxidative damage, but also may act outside the cell 
to promote recovery from brain injury. However the extracellular mechanisms 
involved are currently unclear. The direct extracellular properties of MTs are 
discussed in section 1.4.5. 
Intriguingly, in most cases where MT-I/-II expression is up-regulated, MT-III 
expression is often initially down-regulated, before returning to its original levels 
some time after the original insult (as reviewed by Hidalgo et al, 2001). While the 
reasons underlying the down-regulation of MT-III are not known, this could be due 
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to the different biological properties which these proteins possess, in contrast to their 
shared ability to scavenge free radicals. Furthermore, differences in expression 
profiles following injury may also be due to the different cellular distributions of 
MT-I/-II and MT-III within the brain (Aschner et al, 1997). 
1.4.5 Direct effects of extracellular Mrs upon neurons and astrocytes 
Upon their initial discovery of MT-III, Uchida and colleagues (1991) 
demonstrated that exogenously applied MT-III exhibits neuronal growth inhibitory 
activity upon cultured cortical neurons, while other MT isoforms exhibit no such 
inhibitory activity. To date, a number of reports have confirmed the inhibitory 
activity of MT-III, although in all cases, a crude brain homogenate was required for 
the bioactivity of MT-III (for example, see Erickson et al, 1994; Sewell et al, 1995). 
In all of these assays, MT-I/-II exhibited no inhibitory effect (Erickson et al, 1994; 
Sewell eta!, 1995). 
Intriguingly, in the absence of brain homogenate, extracellular MT-III 
promotes neuronal survival (Sewell et al, 1995). Furthermore, extracellular MT-III 
promotes astrocytic migration following scratch wound injury in culture, although 
MT-Y-II has no such effect (Carrasco et al, 1999). 
Recently, it has been demonstrated that extracellular MT-I/-II is able to 
modulate inflammatory responses to injury. In this regard, MT-I/-II applied 
intraperitoneally following cortical brain injury results in a significant reduction in 
proinflammatory cytokine expression and also decreases reactive gliosis (Penkowa et 
al, 2002). 
These results indicate that MT-I/-II and MT-III exhibit very different 
extracellular properties, despite their high sequence and structural homology. 
However, it is important to note that MTs lack signal peptides or other such 
extracellular trafficking signals, and as such are considered solely intracellular 
proteins (Palmiter et al, 1992). While there are limited reports that cultured cells 
actively release MTs under various conditions (Trayhurn et al, 2000; Uchida et al, 
2002), the mechanism by which this may occur is unknown. Thus, at present, the 
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commonly held view is that the extracellular properties of MTs are artificial 
properties of these proteins, rather than true physiological functions (Palmiter, 1998). 
1.4.6 Metallothioneins in neurodegenerative disorders 
Neurodegeneration is a primary pathological hallmark of a number of 
neurological diseases. In accordance with this, changes in MT expression have been 
noted in a number of these diseases. Following is a brief discussion of some of these: 
1.4.6.1 Multiple sclerosis 
Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the 
CNS. Pathologically it is characterised by cellular infiltration (mostly lymphocytes 
and macrophages), and varying degrees of demyelination and axonal loss (Lassmann 
et al, 1998). As an inflammatory condition, oxidative stress is an obvious candidate 
for involvement in the early stages of MS. Indeed, there is much evidence indicating 
the role of oxidative stress in the development of lesions, one of the hallmarks of MS 
(Lin et al, 1993; De Groot et al, 1997; Vladimirova et al, 1998). Experimental 
autoimmune encephalomyeletis (EAE) is a mouse model of MS, with close 
resemblance to MS both clinically and morphologically (Martin eta!, 1992). 
Juan Hidalgo's lab have extensively investigated the possible roles of MTs in 
EAE, with extremely exciting results. Their initial studies focussed upon the 
expression profiles of the MTs in EAE, and they found a marked difference between 
MT-I/-II and MT-III. Mice with EAE showed significant induction of MT-V-II in the 
spinal cord white matter, and in the brain, though to a lower extent. These proteins 
were prominent in areas of cellular infiltration, with reactive astrocytes and activated 
monocytes/macrophages being the cellular sources of MT-I/-II. Contrastingly, MT- 
expression was unaltered in mice with EAE (Espejo et al, 2001). The relationship 
between MTs and EAE was further elucidated by Hidalgo and colleagues, 
investigating the pro-inflammatory cytokine control of MT expression. Interferon-y 
knockout mice suffer a more severe form of EAE, and induction is 
significantly higher in these mice (Espejo et al, 2001). To confirm their previous 
findings, knockout mice were induced into developing EAE. These mice 
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had a much greater susceptibility to EAE development, and exhibited a significantly 
greater inflammatory response, evidenced by increased macrophage and T-
lymphocytes infiltration in the CNS, while reactive astrogliosis was significantly 
decreased. In addition, the expression of the pro-inflammatory cytokines interleukin-
1 beta, interleukin-6, and tumor necrosis factor-alpha elicited by EAE was further 
increased in the MT-I/-II knockout mice, and oxidative stress and apoptosis were also 
significantly increased in MT-I/-II knockout mice compared to wild type controls 
(Penkowa et al, 2001). Hence, there is significant evidence to suggest a strong 
relationship between the inflammatory response invoked by EAE and metallothionein 
expression. 
1.4.6.2 Alzheimer's disease 
Alzheimer's disease (AD) is a debilitating, age-onset disease, characterised 
clinically by the presence of two pathologic structures found throughout the cortex; 
amyloid plaques and neurofibrillary tangles (Drachman & Lippa, 1992). The 
principal component of amyloid plaques is the P-amyloid peptide which is derived 
from the (3-amyloid precursor protein (Glenner & Wong, 1984; Masters et al, 1985). 
A subset of these 13-amyloid plaques, that are spatially associated with dystrophic 
neurites, are referred to as neuritic or senile plaques. Neurofibrillary tangles consist 
of abnormal filamentous structures (such as paired helical and straight filaments) that 
are derived from the transformation of normal cytoskeletal proteins. Their 
composition is unclear due to their high degree of insolubility, but it is generally 
agreed that the microtubule associated protein, iau, or an abnormal form of this 
protein, is an integral component of neurofibrillary pathology (see review by Vickers 
et al, 2000). The consequence of these structures is extensive neuronal loss, which is 
thought to be closely related to the degree and progression of dementia, the central 
symptom of AD (Vickers, 1997; Vickers eta!, 2000). 
1.4.6.2.1 The discovery of MT-III 
Based upon their previous work, Uchida and colleagues (1989) hypothesized 
that the formation of neurofibrillary tangles, one of the pathological hallmarks of 
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Alzheimer's Disease (AD), was due to an increase in neurotrophic activity in the AD 
brain. Furthermore, they postulated that this increase in neurotrophic activity was 
actually due to the absence of inhibitory factor(s) present within normal brain. This 
idea contradicted the prevailing view at the time, which was that AD was associated 
with a loss of neurotrophic factors in the brain (Appel, 1981). 
In search of these inhibitory factors, Uchida et al (1991) purified and 
characterised a 68 amino acid protein, which they named growth inhibitory factor 
(GIF). They found GIF to be greatly reduced in the AD brain compared to control 
brain. GIF was also found to inhibit survival of cortical neurons in vitro. 
Rather surprisingly, it was discovered that GIF strongly resembled the MT 
family of proteins. The most striking feature of this similarity to MTs was the 
presence of 20 cysteine residues, all of which are conserved between GIF and 
mammalian MTs. These cysteine residues were arranged in either Cys-X-Cys or 
Cys-Cys formations (Uchida et al, 1991). The protein sequence of GIF was 
differentiated from other metallothioneins by two amino acid insertions; a single Thr 
in the N-terminal region, and an acidic hexapeptide in the C-terminal region (Uchida 
et al, 1991; Palmiter et al, 1992). GIF also contained a C(6)PCP motif, which was not 
identified in any other metallothionein isoform (Sewell et al, 1995). 
Further evidence indicating GIF as a member of the metallothionein family 
was obtained from atomic absorption spectrophotometry. Human GIF was found to 
bind three zinc and four copper atoms per polypeptide chain, indicating that like the 
MTs, GIF has a high metal binding activity (Uchida et al, 1991). Molecular analysis 
found the GIF gene to be of similar size, share intron/exon boundaries, and cluster on 
the same chromosome as the other metallothionein isoforms (Palmiter et al, 1992). 
Because of the evidence supporting GIF as a member of the metallothionein 
family, it has been re-named MT-III (Palmiter et al, 1992). 
1.4.6.2.2 The role of MT-III in Alzheimer's Disease 
Since the initial discovery of MT-III, there have been several conflicting 
reports in regards to the changes in MT-III levels within the AD brain, at both mRNA 
(Tsuji et al, 1992; Erickson et al, 1994) and protein level (Uchida et al, 1991; 
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Erickson et al, 1994; Carrasco et al, 1999). These apparently opposing reports may 
be related to issues such as populational differences between the AD brains analysed. 
For instance, Uchida et al (1991) and Tsuji et al (1992) looked at samples from a 
Japanese population (which can be considered a homogenous population), whereas 
Erickson et al (1994) and Carrasco et al (1999) have looked at North American 
populations, which can be considered a mixed population. A recent, comprehensive 
study at both the protein and RNA level involving a large sample size found evidence 
to indicate a down-regulation of MT-III in AD brains (Yu et al, 2001), confirming 
the original observations by Uchida et al (1991). Hence, while MT-III levels in the 
AD brain are unclear, this may reflect the complex nature of the disease. 
The second pathological hallmark of AD, senile plaques, is caused by 
neurotoxic aggegrations of P-amyloid (see review by Selkoe, 1994). Inc & Keung 
(2001) recently reported that MT-III could protect cultured neurons from neurotoxic 
P-amyloid by preventing p-amyloid aggregation, suggesting that MT-III may prevent 
senile plaque formation in AD. 
Again highlighting the significant differences between the metallothionein 
isoforms are the reports that MT-I/-II expression is actually increased in the early 
stages of AD (Adlard et al, 1998; Zambenedetti et al, 1998). The role that MT-I/-II 
may play in the etiology of AD is unclear, but the general consensus is that these 
isoforms are most likely involved in the response to oxidative stress or the mis-
handling of heavy metals, two possible factors in the development of AD (see 
Hensley eta!, 1994; Cuajungco & Faget, 2003 respectively) 
1.4.6.3 Epileptic seizures 
Both MT-V-II and MT-III knock out mice, while appearing phenotypically 
normal during both development and adult life, are extremely susceptible to kainic 
acid induced seizures (Penkowa et al, 1999a and Erickson et al, 1997 respectively). 
Conversely, transgenic mice over-expressing MT-I/-II or MT-III are more resistant to 
kainic acid induced seizures (Penkowa et al, 1999a and Erickson et al, 1997 
respectively). These observations strongly suggest that MTs are involved in seizure 
etiology. Considering the fact that MTs appear to have zinc modulatory properties, 
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this suggests that MTs may be involved in zinc regulation during neural stimulation. 
In this sense, MTs may be important in maintaining intracellular zinc concentrations, 
through recycling or by acting as a zinc reserve. Thus an absence of MT (as 
observed in MT knockout mice) may lead to a rapid decline in intracellular zinc 
during prolonged stimulation (as observed during seizure activity), resulting in a 
reduced capacity to prevent further seizure activity (Erickson et al, 1997). 
Alternatively, it may be that during prolonged neuronal activity, potentially 
toxic influxes of zinc are chelated by intracellular MT. This would suggest that there 
is either a pool of apo-MT (MT not bound to any metal ions) or that MT redistributes 
incoming zinc to locations within the neuron where it is less toxic (Erickson et al, 
1997). Furthermore, intense neuronal excitation also leads to the generation of 
reactive oxygen species (Coyle & Puttfracken, 1993), so MT may also act to protect 
against seizure activity by free radical scavenging. 
1.4.4.4 Familial amyotrophic lateral sclerosis 
Familial amyotrophic lateral sclerosis (FALS) is a progressive disorder 
leading to the death of motor neurons and ultimately death. It has been reported that 
MT-I/-II are up-regulated in this disease, both in humans and in experimental animal 
models of this disease (Blaauwgeers et al, 1996; Gong & Elliot, 2000 respectively). 
One such group of experimental FALS models are those involving mutations in the 
Cu/Zn superoxide dismutase (SOD1) gene. Experiments using both mutant SOD1 or 
knockout SOD1 mice have demonstrated that the disease is caused by a toxic gain of 
function and not by a normal loss of SOD1 activity. While the precise mechanisms 
underlying the toxicity of mutant SOD1 are unclear, abnormalities in zinc binding to 
SOD1 have been implicated in disease pathogenesis (Elliot, 2001). Indeed, recent 
work has found that zinc depleted SOD1 is highly toxic when introduced to cultured 
motor neurons (Estevez eta!, 1999). 
Based upon the zinc binding properties of MTs, it has been hypothesized that 
they could be involved in the progression of FALS through regulating the availability 
of zinc to SOD1. To explore this, the G93A SOD1 mutant mouse was crossed with 
both MT-I/-II and MT-III knockout mice (Puttaparthi et al, 2002). Both of these 
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mice strains exhibited significant reductions in neuronal survival compared to G93A 
SOD1 mutant mice. Additionally, motor dysfunction was markedly accelerated in 
the MT deficient SOD1 mutant mice in a differential manner, in regards to onset 
(MT-I/-II) and progression (MT-III). 
There are a number of ways in which MTs might protect against mutant 
SOD 1-induced toxicity. For instance, in vitro experiments have demonstrated that 
MTs are able to act as a zinc chaperone, ferrying zinc ions to apo-SOD1 (Suzuki & 
Kuroda, 1995). In this regard, in the absence of MTs an inadequate supply of zinc 
might be available to apo-SOD1, particularly in the context that mutant SOD1 has a 
decreased affinity for zinc than wild-type SOD1 (Crow et al, 1997). It is also 
possible that MT may act as a zinc buffer, binding zinc released by mutant SOD1 
(Crow et al, 1997; Elliot, 2001). Alternatively, MT may act in a protective manner 
by scavenging free radicals produced from malfunctioning mitochondria, a prominent 
hallmark of mutant SOD1 induced disease (Dal Canto & Gurney, 1994; Wong et al, 
1995). 
1.5 Concluding remarks 
Within the past 10 years, interest in the potential roles of metallothioneins has 
shifted from metal homeostasis and free radical scavenging to their involvement in 
the cellular response to brain injury as well as in the pathogenesis of a number of 
neurodegenerative disorders. In this regard, it is the neuronal growth inhibitory 
properties of MT-III and the immunosuppressive properties of MT-I/-II that have 
been of most interest. Perhaps the most important point to note in regard to these 
findings is that MT is considered an intracellular protein. The results discussed 
above however, are observations of the effect of MT applied extracellularly either to 
cultured neurons (in the case of experiments investigating the neuronal growth 
inhibitory activity of MT-III) or intraperitoneally following cortical brain injury (in 
the case of MT-I/-II). 
While MT literature contains numerous reports based upon the intracellular 
properties of MTs within the brain, there is little known about the possible 
extracellular, neuroactive roles that these proteins may play. The aim of this thesis is 
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further elucidation of the extracellular, neuroactive properties of brain MTs (MT-I/-II 
and MT-III; MT-IV was not investigated as it is not expressed within the CNS), using 
tissue culture models and an in vivo animal model of neuronal injury. Specifically, 
this will involve: 
1) Characterising the neuroactive properties of an unusual MT-III isoform 
identified previously in this laboratory, sheep MT-III. 
2) Quantitatively measuring the neurite growth inhibitory properties of 
recombinant human MT-III in an embryonic cortical neuron assay system 
(using recombinant human MT-IA for comparison) 
3) Determining whether the extracellular, neuroactive properties of MTs are 
also displayed in an in vivo injury situation, using a model of focal 
cortical brain injury in the adult rat. 
4) Investigating potential cell to cell signaling mechanisms that regulate the 
expression of MT in response to neuronal injury. 
The implications of this work will be considered in evaluating the role of MTs 
in the cellular response to neuronal injury, and also in a therapeutic context. 
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Chapter 2: Materials and Methods 
2.1 Media and buffers 
LB broth 
lOg NaC1 
lOg Tryptone 
5g yeast extract 
dH20 to 1 L, pH 7.0 
4x NuPAGE LDS SDS-PAGE sample buffer 
4g glycerol 
0.682g Tris Base 
0.666g Tris HC1 
0.800g LDS 
0.006g EDTA 
0.75m1 of 1% solution Serva Blue G250 
0.25m1 of 1% solution Phenol Red 
dH20 to 10m1, pH 8.5 
20x NuPAGE MES SDS-PAGE running buffer 
97.6g MES (2-(N-morpholino) ethane sulfonic acid) 
60.6g Tris Base 
10g SDS 
3g EDTA 
dH20 to 500m1, pH 7.3 
SDS-PAGE Coomassie blue staining solution 
500mg Coomassie blue R-250 
500m1 methanol 
100m1 glacial acetic acid 
dH20 to 1L 
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SDS-PAGE destaining solution 
400m1 methanol 
100m1 glacial acetic acid 
dH20 water to 1L 
Bradford protein assay reagent 
100mg Coomassie Brilliant Blue G-250 
50mls 95% ethanol 
100mls 85% orthophosphoric acid 
dH20 to IL 
filtered before use 
Recombinant protein resuspension buffer 
20mM Tris-HC1, pH 7.6 
1mM DTT 
0.02% NaN3 
dH20 to 1L 
G-75 elution buffer 
20mM Tris-HC1, pH 7.6 
1mM DTT 
0.02% NaN3 
dH20 to IL 
DEAE elution buffer 
20mM Tris-HC1, pH 7.6 
1mM DTT 
appropriate NaC1 concentration 
0.02% NaN3 
dH20 to IL 
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20x NuPAGE western blotting transfer buffer 
10.2g Bicine 
13.08g Bis-Tris 
0.75g EDTA 
dH20 to 125m1, pH 7.2 
PBS-Tween buffer  (Western Blotting) 
10 PBS tablets (Sigma) 
1ml Tween 20 
dH20 to IL 
5% Blocking Solution  (Western Blotting) 
5g Diploma Skim Milk Powder 
PBS-Tween buffer to 100m1 
2.2 Production of recombinant MT proteins 
2.2.1 Overview of bacterial expression of recombinant Ml's 
PET-3d (Novagen) expression vector constructs containing inserts coding for 
sheep MT-III, as well as human MT-IA and human MT-III have been previously 
constructed in this laboratory (sheep and human MT-III: Chung, 1999, BSc Hons 
thesis; human MT-IA: Eckhardt, 2000, BSc Hons thesis). Their structure has been 
examined by DNA sequencing, confirming the presence of the correct insert and that 
this insert is in the correct reading frame. Note that previous work had resulted only 
in the production of these recombinant MT expression vectors. 
The MT expression vectors were transformed into BL21(Plys) host cells, an 
E.coli strain which contains a chromosomal copy of the T7 RNA polymerase gene. 
These hosts are lysogens of bacteriophage DE3, a lambda derivative that carries a 
DNA fragment containing the lad I gene, the lacUV5 promotor, and the gene for T7 
RNA polymerase (Studier and Moffat, 1986). Once a ADE3 lysogen is formed, the 
only promoter known to direct transcription of the T7 RNA polymerase gene is the 
lacUV5 promoter, which is inducible by isopropyl-p-D-thiogalactopyranoside 
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(IPTG). Addition of IPTG to a growing culture of the lysogen induces T7 RNA 
polymerase, which in turn transcribes the target DNA in the plasmid. The bacterial 
expression protocol is described briefly in Figure 2.1. 
2.2.2 Induction of bacterial expression 
A 5m1 LB broth solution (with 100p,g/m1 ampicillin) was inoculated with the 
appropriate expression vector (transformed into BL2 I host expression cells), and 
incubated overnight at 37°C with shaking. In the morning, the cells from this 5m1 
starter broth were used to inoculate 400mls of fresh LB broth in a 1L conical flask (to 
ensure good aeration). The flask was incubated with shaking at 37°C until 0D600 
reached 0.6. Bacterial expression was then induced by the addition of IPTG to a final 
concentration of 0.4mM, and incubation continued for 3 hours. At 30 minutes post 
IPTG induction, 1mM of ZnSO4 was added to form Zn-MT complexes from the 
freshly produced recombinant apo-MTs. This provides the basis of detection of the 
recombinant MTs during latter stages of purification. 
After 3 hours, the cells were placed on ice for 5 minutes. They were then 
harvested by centrifugation at 5000g for 20 minutes at 4°C. The pelleted cells were 
then resuspended in 10mls of recombinant protein resuspension buffer, and freeze-
thawed twice at —20°C. Cellular debris was pelleted by centrifugation at 2000g for 2 
minutes, and the supernatant (containing recombinant Zn-MTs) collected for further 
purification. 
2.2.3 Anion exchange chromatography 
Supernatants were applied to a Whatmans DEAE cellulose column (0.75 x 
7cm, Pharmacia) equilibrated with elution buffer (20mM Tris-HC1, pH 7.6, 1mM 
DTT, 0.02% NaN3). Fractions were eluted using a linear NaCl gradient, at a flow 
rate of 0.4m1/min, and their zinc content determined by atomic absorption 
spectrophotometry (AAS, Varian Techtron 1000). Zn-containing fractions were 
pooled and concentrated by ultrafiltration (MW cut-off 5 lcD, Millipore). 
To determine the NaCl gradient, fractions were eluted in the absence of MT 
sample, and the conductivity of each fraction assessed using a conductivity meter 
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2.2.4 Storage of recombinant MTs 
Purified recombinant MTs were stored as apo-MTs (metal free MTs) in acidic 
conditions, as suggested by Denis Winge (personal communication). Briefly, 
recombinant MTs were acidified with dilute HC1 to pH 2.0, and bound Zn(II) ions 
removed by • applying the sample to an ultrafiltration column. The apo-
metallothionein was stored in aliquots at —80°C until required. When required, the 
apo-metallothionein was reconstituted with Zn(II) by the addition of 7.5mol 
equivalents (for human MT-III and MT-IA), and 5.5mol equivalents (for sheep MT-
III) of Zn(u), followed by neutralization of the sample to pH 8.0 with 20mM Tris-
HC1. The sample was desalted by ultrafiltration. 
2.2.5 SDS-PAGE of recombinant MTs 
Samples were prepared for SDS-PAGE by adding 16.5[11 of sample to 7.5R1 
of 4x NuPage LDS sample buffer, vortexing, and addition of 6[xl of NuPage 10x 
Reducing Agent (0.5M DTT). The samples were heated for 10 minutes at 70°C and 
electrophoresed on a Novex, ready made 10% NuPage Bis-Tris gel (Invitrogen) in lx 
MES buffer, under reducing conditions. Immediately after electrophoresis, the gel 
was removed and incubated in Coomassie blue staining solution for 2 hours, followed 
by de-staining. 
2.2.6 Metal binding analysis of recombinant MTs 
The Bradford protein assay, a sensitive Gig quantities) protein-dye assay 
(Bradford, 1976) was used to quantify recombinant protein concentrations. Briefly, 
this involved diluting the MT sample with Bradford reagent, and subsequent protein 
binding assessed by spectrophotometry at A595nm• Quantification was performed 
using a standard curve with bovine serum albumin (BSA). Subsequently, the zinc 
content of known recombinant MT protein amounts was measured by AAS. From 
this, the molar equivalent of metal ions bound to recombinant MT was determined. 
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2.2.7 Western blotting analysis of recombinant human MT-HA 
Western blotting was performed using a modified method of Whitacre (1996). 
Briefly, the proteins were electro-transferred from the SDS-PAGE gel to a 0.45[tm 
nitrocellulose membrane (Advantec MFC). After blocking with 5% skim milk in 
Phosphate Buffered Saline-Tween 20 buffer (PBS-T), the filter was washed three 
times in PBS-T, followed by incubation overnight with primary antibody (anti-MT- 
DAKO) at a dilution of 1:500 in PBS-T. The following morning, the membrane 
was washed in PBS-T, and then incubated with secondary antibody (anti-mouse Ig 
HRP linked antibody, Amersham) at a dilution of 1:1000 in PBS-T. Following three 
washes in PBS-T, detection was performed using the Lumi-light Western Blotting 
Substrate Kit (Boehringer Mannheim), and the membrane placed in a x-ray cassette 
and exposed to Hyperfilm ECL for varying exposure times. The specificity of the 
MT 4/-II antibody has been tested previously (Skabo et al, 1997), and shows no 
cross-reaction with any other MT isoforms. 
2.3 Primary cell culture, and immunocytochemical analysis 
2.3.1 Low density neuron cultures 
All procedures involving animals were approved by the Animal 
Experimentation Ethics Committee of the University of Tasmania and are consistent 
with the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes. Cortical tissue was removed from embryonic day 18 (sperm positive day = 
El) Hooded Wistar rat embryos and incubated in sterile 10mM HEPES buffer 
(37°C). This was followed by trypsin digestion (0.25%, Sigma), followed by 
addition of trypsin inhibitor (40 BTEE units/mg protein; Sigma). Three gentle washes 
of the cell pellet were made using fresh HEPES buffer. The cell suspension was then 
triturated carefully using a lml pipette, and filtered through gauze of pore size 601.tm. 
Cell counts were performed by trypan blue exclusion. This involved suspending a 
lOtil aliquot of cell suspension with 101A1 of trypan blue, and viable cells (those that 
exclude dye and are hence white) were counted. , Cells were then plated onto glass 
coverslips (132mm2) pre-coated overnight with poly-L-lysine (0.01%, Sigma), at a 
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cell density of 5x10 4 cells/well, with 150 .is/m1 rat brain extract added. Cultures 
were maintained at 37 °C in humidified air containing 5% CO2 for 3 days after MT 
addition. A specific culture medium developed for selective neuronal growth was 
used (Brewer, 1995; 1997), consisting of NeurobasalTM  medium (GIBCO), 
supplemented with 0.1% (f/c) B-27 supplement (GIBCO), 0.2% N2 supplement 
(GIBCO) 0.1mM (f/c) L-glutamine (Sigma), and 200U/mlgentamicin (GIBCO). 
2.3.2 Neuron cluster cultures 
2.3.2.1 Culturing techniques 
Neurons were obtained as described above, except that the neurons were 
plated directly from the unfiltered cell suspension onto glass coverslips (254mm 2 , 
pre-coated overnight with 0.01% poly-L-lysine) at a cell density of 4.5x105 
cells/well, and incubated overnight at 37 °C, 5% CO2. The increased plating density 
promotes neuronal cluster formation, with thick axonal bundles forming between the 
clusters (Dickson et al, 2000). The next day, the culture medium was replaced with 
fresh medium, and the neurons maintained for 21 days (initial plating is day 0), with 
the medium replaced with fresh medium every 4 days. The medium used was as 
described previously for single cell neuron cultures. 
2.3.2.2 Transection of neurite bundles 
Transection of axonal bundles was essentially as described previously 
(Dickson et al, 2000). Briefly, at 20 days after initial plating, coverslips were moved 
to individual petri dishes (approximately 2900mm 2) with 150 p..g/m1 rat brain extract 
added. The following day, neurite bundles were transected on an inverted 
microscope (Leitz Fluovert) using a fine goniotomy knife (Kaisers). 
2.3.3 Neuron/astrocyte co-cultures 
Cortical tissue was removed from embryonic day 19 (sperm positive day = 
El) Hooded Wistar rat embryos and incubated in sterile 10mM HEPES buffer 
(37°C). This was followed by trypsin digestion (0.25%, Sigma), followed by 
addition of trypsin inhibitor (40 BTEE units/mg protein; Sigma). Three gentle washes 
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of the cell pellet were made using fresh HEPES buffer. The cell suspension was then 
triturated carefully using a 1 ml pipette. The cells were counted by trypan blue 
exclusion, and plated onto glass coverslips (132mm 2) pre-coated overnight with poly-
L-lysine (0.01%), at a cell density of 1x10 6 cells/well. Cultures were maintained at 
37°C in humidified air containing 5% CO2. The culture medium consisted of 
NeurobasalTM medium (GIBCO), supplemented with 0.1% (f/c) B-27 supplement 
(GIBCO), 0.1mM (f/c) L-glutamine (Sigma), and 200U/m1 gentamicin (DBL). 
Media was changed every 3 days for the first week, and then every 7 days for the 
next two weeks. Only half of the media in the well was replaced at each media 
change. This allowed astrocytes present within the culture to enrich the medium with 
growth promoting factors (such as neurotrophins) promoting their survival and 
proliferation. In some cases, scratch wound injuries were performed. Scratch 
wounds were performed using a fine goniotomy knife (Kaisers). 
2.3.4 Fluorescent immunocytochemical analysis of primary cultures 
At the appropriate time, cells were fixed with 4% paraformaldehyde, for 20 
minutes at room temperature. Coverslips were then incubated with a variety of 
primary antibodies (see Table 2.1) diluted in 0.1% PBS, 0.03% tritonX-100 
(immunofluorescence diluent). 
Coverslips were then incubated with two secondary antibodies (goat anti-
mouse IgG conjugated to Alexafluor 488 and goat anti-rabbit IgG conjugated to 
Alexafluor 594, 1:1,000 dilution; Molecular Probes), applied in 0.1% PBS. 
Following 3 washes in PBS and drying, the coverslips were mounted onto slides 
using Permafluor mounting medium (Immunotech). In some cases nuclear yellow 
staining was performed. Following immunocytochemistry, a 0.1% solution of 
nuclear yellow was applied to the coverslip, and incubated at room temperature for 5 
minutes, and the coverslip subsequently washed 3 times with PBS. 
In some experiments, triple immunofluorescence was performed using three 
primary antibodies: anti-MT-I/-II, anti-13111 tubulin (monoclonal mouse antibodies) 
and anti-GFAP (polyclonal rabbit). Coverslips were incubated with anti-MT-I/-II 
(diluted 1:200 in diluent) for 1 hour at room temperature, with shaking. Following 
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Antibody name Type Immunoreactivity Dilution Source ' Reference 
anti-MAP2 M Microtubule-associated protein 2 1:1,000 Chemicon Binder et al, 1984 
Neuron specific p-tubulin subunit of 
anti-pill tubulin M the tubulin monomer 1:10,000 Promega Lee et a!, 1990 
Metallothionein-I and -II isoforms 
anti-MT-U-11 M only 1:500 DAKO Skabo eta!, 1997 
anti-tau R 
Microtubule-associated tau protein, 
axonal 1:5,000 DAKO Goedart et al, 1988 
anti-NFM R Neurofilament, medium subunit 1:1,000 Serotec Karlsson eta!, 1987 
anti-GFAP R Glial fibrillary-associated protein 1:500 DAKO Viale eta!, 1991 
Table 2.1: A list of the various primary antibodies used for immunohistochemical 
staining. Antibodies were either monoclonal mouse (M) or polyclonal rabbit (R). 
three washes in PBS, coverslips were incubated with goat anti-mouse IgG conjugated 
to Alexafluor 488 (Molecular Probes) at 1:1,000 (in PBS) for 1 hour at room 
temperature with shaking. This was repeated, and coverslips subsequently washed 
three times in PBS. This, and all later steps were performed in the dark to preserve 
fluorescence. Anti-r3III tubulin (1:5,000) and anti-GFAP (1:2,000) were applied to 
coverslips in PBS for 1 hour at room temperature, with shaking. Following three 
PBS washes, goat anti-rabbit IgG conjugated to Alexafluor 594 (1:2,000; Molecular 
Probes) and sheep anti-mouse IgG conjugated to AMCA (1:500; Vector) were 
applied to coverslips in PBS for 1 hour. Following three PBS washes, coverslips 
were dried and mounted onto slides using Permafluor mounting medium 
(Immunotech). 
In some experiments, cell viability was determined by propidium iodide 
uptake. Briefly, 50ug/m1 of propidium iodide was added to cultures for 30 minutes, 
followed by fixation as described previously. Those cells which take up propidium 
iodide (and which are hence unviable) were visualized on fluorescent microscope at 
594nm (Texas Red filter). 
2.4 Rat focal cortical brain injuries, and immunohistochemical analysis 
2.4.1 Rat focal cortical brain injuries 
Rat focal cortical injuries were made as reported previously (King et al, 
1997). Briefly, 250g male rats were anaesthetised with 0.1m1/100g of Nembutal 
(sodium pentobarbitol), the head shaved, and the rat then immobilised in a Stoelting 
stereotaxic frame. An incision down the midline of the skull was made, and a hole 
carefully drilled through the skull above the Par 1 region of the somatosensory cortex 
using a Dremel surgery drill. A Hamilton syringe with a 25 gauge bevelled needle 
was aligned with the hole, and then lowered 1.5nun into the brain. After 10 minutes, 
the syringe was slowly removed and the hole within the skull filled with gelfoam 
(such that the gelfoam sits above the injured cortex), pre-treated with either 20R1 of 
phosphate buffered saline (PBS) or 20t11 of MT-IA (5n/ml concentration). 
Antiseptic powder was applied, and then the skin pulled back over the skull and held 
together by 2 staples. 
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2.4.2 Vibratome sectioning 
At the appropriate time, rats were re-anaesthetised and transcardially perfused 
with 100m1 PBS followed by 100m14% paraformaldehyde at a flow rate of 8m1/min. 
Brains were removed and post-fixed overnight in 4% paraformaldehyde at 4 °C. They 
were then embedded in 5% agar (in 0.1% PBS), and sectioned by vibratome at a 
thickness of 50[Im (Leica VT1000E). Sections were then used in fluorescent 
immunohistochemistry as described below or stored in PBS (containing 0.01% 
sodium azide) at 4°C. 
2.4.3 Fluorescent immunohistochemisuy of brain sections 
Brain sections were incubated with a combination of two primary antibodies; 
mouse SMI-312/rabbit anti-ferritin (1:2,000 Sternberger Monoclonals; 1:10,000 
ICN), or SMI-312/rabbit anti-GFAP (1:500 Sternberger Monoclonals; 1:2,000 
DAKO). Anti-ferritin was used as a marker of activated microglial cells (King et al, 
2001). SMI-312 labels the phosphorylated form of neurofilaments (NF), and is 
considered an axonal marker (Ulfig eta!, 1998). The antibodies were diluted in 0.1% 
PBS, 0.03% tritonX-100. Sections were then incubated with two secondary 
antibodies (goat anti-rabbit IgG conjugated to alexafluor 488, 1:250 dilution, 
Molecular Probes; and horse anti-mouse rat adsorbed IgG, 1:250 dilution, Vector) 
applied in 0.1% PBS. Brain sections were mounted using Permafluor mounting 
medium (Immunotech). Specimens were viewed on the BX-60 (Olympus) 
fluorescence microscope. 
2.5 Miscellaneous techniques 
2.5.1 G-75 gel filtration chromatography 
To calibrate the column, a 10m1 sample of protein standards (10mg each of 
Blue Dextran, cytochrome c, and potassium ferrocyanate) was evenly applied to a 
Sephadex G-75 column (31.5 x 2.75 cm, Pharmacia) equilibrated with G-75 elution 
buffer (20mM Tris-HC1, pH 7.6, 1mM DTT, 0.02% NaN3). The sample was allowed 
to run down until only a very small amount covered the top of the Sephadex beads. 
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Elution buffer was then evenly applied to the top of the column and a gravity feed 
attached. The sample was eluted with elution buffer at a flow rate of 1.2m1 per 
minute, and collected in 3m1 fractions. Protein content of these standards was 
determined using ultraviolet (UV) spectrophotometry (BIOCHROM Ultraspec II) at 
230nm. 
Samples were applied to the column, and eluted under the same conditions as 
above. The protein content of each fraction was assessed by the method of Bradford 
(1976). 
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Chapter 3: An unusual mammalian MT-III variant, sheep MT-III 
3.1 Introdtiction 
The mammalian MT family consists of 4 isoforms, within which a number of 
sub-isoforms exist. It is striking, however, that none of these exhibit alterations in 
the number or position of the consistently conserved cysteine residues. This suggests 
a tight evolutionary constraint, with these conserved cysteine residues being essential 
to the physiological role of the MTs. However, characterization of cDNAs of sheep 
MT-III in our laboratory by Adele Holloway (Holloway, 1996, PhD thesis) suggested 
that the sheep MT-III gene might encode a variant protein (Figure 3.1). Using 
standard metallothionein protein isolation techniques (including heat treatment, 
solvent precipitation, gel filtration and anion exchange chromatography) the sheep 
MT-III protein has been isolated and purified by the author, as part of his BSc 
Honours studies, confirming that sheep do indeed produce a naturally occurring MT-
III variant (Chung, 1999, BSc Hons thesis). Indeed, partial amino acid sequencing 
confirmed the aberrant nature of the sheep MT-III protein. 
Of particular interest within the sheep MT-III protein is the absence of 3 
cysteine residues, 2 by deletion and one by substitution (with reference to other 
characterised MT-III proteins). Previous studies have found that experimental 
alterations in the cysteine residues of MTs significantly affects the conformation of 
the protein, its metal binding properties (Cismowski & Huang, 1991), and consequent 
physiological functions such as metal detoxification (Cismowski & Huang, 1991; 
Chemaik & Huang, 1991). As such, the absence of 3 cysteine residues in sheep MT-
III is likely to alter the conformation of the protein, and it would seem feasible then, 
that sheep MT-III would have altered metal binding properties (Figure 3.2), and as a 
consequence altered physiological properties. Intriguingly, sheep have been found to 
exhibit a high sensitivity within the brain to dietary fluctuations in heavy metals, and 
in particular copper (Alleyne et al, 1998; Doherty et al, 1969; Howell et al, 1964). It 
is known that expression and structure of sheep MT-I/-II isoforms are similar to their 
other mammalian counterparts (Peterson et al, 1988), so this marked sensitivity may 
be related to the variant sheep MT-III protein. 
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	1 	 11 	 21 	 30 
Sheep MT-Ill MDPEACPCPT GGSCTCSDSC KCEGCTCASS 
1 	 11 	 21 	 30 
Human MT-III MDPETCPCPS GGSCTCADSC KCEGCKCTSC 
1 	 11 	 21 	 30 
Mouse MT-III MDPETCPCPT GGSCTCSDKC KCKGCKCTNC 
31 	 41 	 51 	 61 	68 
Sheep MT-III KK - - - SCCPA ECEKCAKDCV CKGGEGAEAE EKKCGCCQ 
* * 
31 	 41 	 51 	 61 	68 
Human MT-III KKSCCSCCPA ECEKCAKDCV CKGGEAAEAE AEKCSCCQ 
31 	 41 	 51 	 61 	68 
Mouse MT-III KKSCCSCCPA GCEKCAKDCV CKGEEGAKAE AEKCSCCQ 
Figure 3.1: The predicted protein sequence (from mRNA) of sheep MT-III was 
compared to known human and mouse MT-III protein sequences. There is a 3 amino 
acid deletion (SCC) in sheep MT-III, normally conserved at positions 33-35 of MT-
III proteins, as well as a C_S change at position 30. Amino acids found in the sheep 
MT-III protein but not in human or mouse MT-III, are indicated by asterisks. Data 
from Holloway, 1996, PhD thesis. 
CdIV CdIII CdII CdV CdVII CdVI Cdl 
rat liver MT 
MDPN-CSCATDGSCSCAGSCKCKQCKCTSCKKSCCSCCPVGCAKCSQGCICKE ASDKCSCCA 
mouse MT-III 
MDPETCPCPTGGSCTCSDKCKCKGCKCTNCKKSCCSCCPAGCEKCAKDCVCKGEEGAICAEAEKCSCCQ 
CdIV CdIII CdII CdV 
	CdVII CdVI 
	
Cdi 
- sheep MT-III 
MDPEACPCPTGGSCTCSDSCKCEGCTCASSKIC---SCCPAECEKCA1CDCVCKGGEGAEAEEKKCGCCQ 
Figure 3.2: Cadmium-thiolate linkages in rat liver I i3Cd7-thionein have been 
determined by NMR spectroscopy (adapted from Kagi and Schaffer, 1988) and using 
this structure as a model, a proposed structure for the cadmium-thiolate linkages of 
mouse MT-III is shown. This structure is based upon reports indicating that MT-III 
exhibits a similar metal-protein conformation to the MTI/II class of isoforms (as 
reviewed by Romero-Isart & Vasak, 2002). In comparison, the altered cysteine 
complement of sheep MT-III is likely to disrupt metal-thiolate linkages affecting 
binding to at least three metal atoms (dotted lines). Adapted from Holloway, 1996, 
PhD thesis. 
While the physiological role of MT-III is unknown, MT-III has been 
demonstrated to have neuronal growth inhibitory properties in culture models (for 
example see Uchida et al, 1991). Later studies defined the C (6)PCP region of the 
protein as responsible for MT-III's inhibitory properties (Sewell et al, 1995). All 
mammalian MT-III isoforms isolated to date possess this C(6)PCP motif, and 
subsequent inhibitory properties. Interestingly, the variant sheep MT-III protein also 
contains this motif (Figure 3.1), suggesting that it also shares the inhibitory properties 
of other MT-III isoforms. 
The aim of this chapter is two-fold. Firstly, because sheep MT-III is the only 
known MT variant expressed at the protein level to exhibit changes in its cysteine 
distribution, the physical consequences of these changes will be compared to other, 
well characterized MTs, namely human MT-IA and human MT-III. These 
experiments may elucidate potential mechanisms underlying the marked sensitivity 
of sheep to heavy metal induced neurotoxicity. The sheep MT-III variant will also be 
assessed functionally, by comparing its biological activity (namely neuronal growth 
inhibition) to human MT-IIA and MT-III. This may indicate the importance of this 
novel extracellular property of MT-III, and also provide further insight into the 
structural features of the MT-III molecule responsible for this activity. 
3.2 Experimental Procedures 
3.2.1 Overview of recombinant MT production 
Metallothionein is well suited to recombinant bacterial production, because it 
is a small, single-chain peptide with no known post-translational modifications, or 
internal disulphide linkages, pET-3d expression vector constructs (Novagen) 
containing inserts coding for sheep MT-III, as well as human MT-IIA and human 
MT-III have been previously constructed in this laboratory (sheep and human MT-
III: Chung, 1999, BSc Hons thesis; human MT-IIA: Eckhardt, 2000, BSc Hons 
thesis) The important features of this vector are ampicillin resistance, and inducibility 
of target gene expression by addition of the galactose analogue isopropyl-P-D-
thiogalactopyranoside (IPTG). The addition of IPTG induces the production of T7 
RNA polymerase within the host bacterium, which in turn transcribes the MT insert 
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in the plasmid. T7 RNA polymerase is so selective and active that almost all of the 
cell's resources are converted to target gene expression. As such, the desired protein 
product can comprise more than 50% of the total cell protein after a few hours of 
induction (Studier & Moffat, 1986). Mammalian MT sequences were derived from 
mRNA by RT-PCR, at the same time incorporating Ncol and BamH1 restrictions 
sites at appropriate locations using mismatched primers. The structure of all 
constructs has been examined by DNA sequencing, confirming the presence of the 
correct insert, and that this insert is in the correct reading frame (Figure 3.3). 
All of the recombinant proteins were expressed in E.coli in the presence of 
zinc, to produce Zn-MT conjugates, which are less readily oxidized than apo-MT 
(Hong et al, 2001). Furthermore, zinc forms the basis of recombinant MT detection 
during purification by chromatography. Each recombinant MT isoform was 
produced in a separate run, to avoid possible contamination between batches. 
Proteins were isolated from bacterial pellets by a combination of heat treatment, 
anion-exchange chromatography and ultrafiltration as described in Figure 2.1 
(Chapter 2). 
3.2.2 Functional analysis of recombinant sheep MT-III 
The metal binding properties of recombinant MT proteins were determined by 
firstly quantifying recombinant protein concentrations using the Bradford protein 
assay (Bradford, 1976). Subsequently, the zinc content of known recombinant MT 
protein amounts was measured by atomic absorption spectrophotometry (AAS). 
From this, the molar equivalent of metal ions bound to recombinant MT was 
determined. 
3.2.3 Neuronal growth inhibitory activity of recombinant sheep MT-III 
The neuronal growth inhibitory activity of sheep MT-III was investigated 
using the model first described by Uchida et al (1991). Recombinant MTs were 
applied to low density (5x10 4 cells/well) embryonic cortical neuron cultures 
immediately after initial plating, together with 1501.1g/m1 brain extract. Control 
cultures received brain extract only. For analysis, 10 digital images were captured 
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• target gene 
coding region ampicillin resistance 
gene 
pET-3d cloning/expression region 
T7 promoter 
TAATACGACTCACTATAGGGAGACCACAACGGTT TCCCTCTAGAAATAATTTTGT T TAACT TTAAGAA 
GGA 
	
Ncol 	sheep MT-III 	coding region 	 Bamhl 
GATATTACCATGGACCCTGAGGCCTGCCCCTGCCCT 	AAGTGCGGCTGCTGCCAGTGAGGATCC  
GGC 
MetAspProGluAlaCysProCysPro 	LysCysGlyCysCysGlnEnd 
T7 terminator 
•	  
TGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAA  
Figure 3.3: cDNA encoding the sheep MT-III protein (indicated in red) was inserted 
into the pET-3d expression vector, using the Ncol and BamH1 restriction enzyme 
sites. Expression of MT-III protein is controlled by the T7 promotor (arrow). The 
expression vector is transferred to a host E.coli strain with a chromosomal copy of 
the T7 RNA polymerase gene, under the control of the lacUV5 promoter, which can 
be induced by IPTG. Hence, addition of IPTG induces T7 RNA polymerase 
production, which subsequently transcribes the sheep MT-III DNA. 
from each coverslip at 3 days post MT treatment, at a magnification of 40x (Olympus 
BL-51 microscope, Olympus DP-50 digital camera). The number of neurons counted 
per coverslip ranged from 50 to 120 cells. Experiments were replicated in triplicate. 
Growth inhibitory activity was determined in a similar manner to that of Uchida et al 
(1991) as a percentage by the following formula: percentage inhibition = 100 — (100 
x the number of neurons per field of view in the presence of added recombinant 
MT)/( the number of neurons in control cultures). Student t-test analysis was 
performed using SigmaStat (Jandel Scientific Software Corporation; San Rafael, 
CA). 
3.3 Results 
3.3.1 Bacterial expression of recombinant MTs 
At the commencement of this work, pET-3D expression vectors for sheep 
MT-III and human MT-HA and MT-III had been constructed (Chung, 1999, BSc 
Hons thesis; Eckhardt, 2000, BSc Hons thesis), but protocols for bacterial expression, 
MT isolation and purification, and characterization had not been developed in this 
laboratory. Therefore, the initial aim of this chapter was to complete this work, so as 
to provide recombinant MT protein for further experimentation. Briefly, bacterial 
cultures were grown to an optical density of 0.6, at which time MT protein 
expression was induced by addition of IPTG for a period of 3 hours in the presence 
of 1mM zinc sulphate. Recombinant protein expression was confirmed by SDS-
PAGE, using samples at the start and end of the expression period (Figures 3.4A and 
3.4B). Before induction of MT protein expression, it was clear that there was no 
protein band at the 7kD size range (the approximate size of MTs as assessed by SDS-
PAGE is 6-71(D). At 3 hours post induction, a dense protein band was clearly visible 
at 71c13. Furthermore, there was little difference in the intensity of higher molecular 
weight protein bands between time points, indicating that the bacterial cells are not 
dividing and are almost exclusively producing recombinant protein. 
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Figure 3.4A: SDS-PAGE analysis of recombinant MT-III protein expression. 
Samples were taken both prior to IPTG induction of protein expression and after 3 
hours of expression. Lanes contained the following: 
Lane 1 — molecular weight markers 
Lane 2 - human MT-III, bacterial lysate prior to IPTG induction 
Lane 3 - human MT-III, bacterial lysate 3 hours post induction 
Lane 4 - sheep MT-III, bacterial lysate prior to IPTG induction 
Lane 5 - sheep MT-III, bacterial lysate 3 hours post induction 
At 3 hours post induction, a protein band corresponding to recombinant MT-III was 
clearly visible at 7kD (arrow). 
185kD 
9810 
52kD 
31 kD 
17/19kD 
11kD 
6kD 
3kD 
Figure 3.4W SDS-PAGE analysis of recombinant human MT-IA protein 
expression. Samples were taken both prior to IPTG induction of protein expression 
and after 3 hours of expression. Lanes contained the following: 
Lane 1 — human MT-IA, bacterial lysate prior to IPTG induction 
Lane 2— human MT-IA, bacterial lysate 3 hours post induction 
Lane 3 — native sheep MT-I/-II (used as a molecular weight marker for MT, 
and also as a positive control for western blotting) 
Lane 4— molecular weight markers 
At 3 hours post induction, a protein band corresponding to recombinant MT-IA was 
clearly visible at 710 (arrow), which was also similar to the electrophoretic position 
of native sheep MT-I/-II. 
3.3.2 Isolation and purification of recombinant MTs 
Following expression, the bacterial cells were pelleted and carefully lysed by 
freeze thawing. Following lysis, bacterial cell debris was pelleted, and the 
supernatant (containing recombinant MT) was heat treated at 65°C for 10 minutes. 
Heat treatment resulted in the precipitation of a number of proteins, which were 
removed by centrifugation. 
Further purification of the recombinant MTs was achieved by anion-exchange 
chromatography using DEAE cellulose at pH 7.6 (see Chapter 2.2.3). A NaCl 
gradient was used to elute recombinant proteins from this column. These proteins 
were found to elute at various salt concentrations, ranging from 100mM (human MT-
IA-Figure 3.5A) to 200mM (human MT-III-Figure 3.5B) to 250mM (sheep MT-III-
Figure 3.5C). These points of elution are similar to those observed previously for 
native MTs. For instance, MT-II isoforms have been eluted at salt concentrations 
ranging from 80-120mM (Nordberg et al, 1972; Hidalgo et al, 1989), whilst various 
mammalian MT-III isoforms have been eluted at concentrations near 200mM 
(including 200mM for human MT-III, Uchida et al, 1991; 230mM for porcine MT-
III, Chen et al, 1996). Native sheep MT-III has been eluted at 250mM NaC1 
concentration (Chung, 1999, BSc Hons thesis). 
Collected fractions were concentrated by ultrafiltration, and analysed by SDS-
PAGE (Figure 3.6). All recombinant MT proteins electrophoresed as a single band at 
the expected size (approximately 71(Da), indicating the absence of any contaminating 
bacterial proteins, or oxidation of the recombinant MTs during the purification 
process. 
Identification of the purified recombinant proteins as MTs was based upon 
their electrophoretic position in SDS-PAGE analysis, their zinc binding ability and 
their elution profiles when purified by anion-exchange chromatography. Western 
blotting analysis has also been performed for recombinant human MT-IA as further 
confirmation of the protein expression process (results not shown). This was not 
possible for recombinant MT-III due to the lack of antibodies which bind to MT-III. 
32 
A
b
so
rb
an
ce
  (
A2
14
) 
2.5 
2 
1.5 
1 
0.5 
0 
- 300 
2 
- 250 E 
- 200 
- 150 "E' 
0 
- 100 g 
c.) 
0 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
fraction number 
N- 
‘- 	" Cr) C71 7.1 1(:), 	Fi)N 
Fraction number 
- 350 
_300 
- 250 1- 
- 200 II 
- 150 8 
- 100 8 
- 5r) be; 
0 
2 - 
1.8 - 
1.6 - 
1.4 - 
1.2 - 
1 - 
0.8 - 
0.6 - 
0.4 - 
0.2 - 
0 
A
b
so
rb
an
ce
  (
A2
14
) 
A
b
so
rb
an
ce
  
1.6 - 
1.4 - 
1.2 - 
1 - 
0.8 - 
0.6 - 
0.4 - 
0.2 - 
0 
- 350 
- 300 E 
- 250 S 
- 200 E 
- 150 8 
- 100 8 
- 50 (7. 
0 
Cr) (13 N- 	 Cr) Ill 	 •- (r) 	N- 0) N- Cr) 
	  CNI 	 CNI Cr) CO 
Fraction Number 
Figure 3.5: Recombinant MT proteins were purified by anion-exchange 
chromatography. MTs were eluted using a salt gradient ( 41), and detected by the zinc 
content of individual fractions using AAS at a wavelength of 214nm ( • ). Human 
MT-IA was eluted from the column at 100mM salt concentration (A). Human MT-
III (B) eluted from the column at 200mM salt concentration and sheep MT-III (C) at 
a concentration of 250m1v1. 
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Figure 3.6: SDS-PAGE analysis of recombinant MT-III purification by anion 
exchange. Following anion-exchange chromatography of crude bacterial extracts, the 
peaks exhibiting high zinc content were pooled and concentrated by ultrafiltration. 
These samples were then analysed by SDS-PAGE. Lanes contained the following: 
Lane 1 — human MT-III, crude bacterial extract 
Lane 2— sheep MT-III, crude bacterial extract 
Lane 3 — anion-exchange purified human MT-III 
Lane 4— anion-exchange purified sheep MT-III 
Lane 5— molecular weight markers 
Purified recombinant MT-III electrophoresed as a single protein band at 
approximately 6-71d) (as indicated by arrow). 
3.3.3 Metal binding analysis of recombinant MT proteins 
The stoichiometry of metal-protein binding of recombinant sheep MT-III was 
compared to the known properties of human MT-IA and human MT-III by atomic 
absorption spectrophotometry. Recombinant sheep MT-III bound 5 zinc ions per 
molecule, while both recombinant human MT-III and human MT-IA were found to 
bind 7 zinc ions per molecule. 
3.3.4 Neuronal growth inhibitory activity of recombinant sheep MT-III 
The neuronal growth inhibitory activity of recombinant sheep MT-III protein 
(compared to vehicle treated cultures and determined as % inhibitory activity) was 
found to be 14% and 37% at lpg and 5g/ml respectively. This was compared to the 
activity of other MT isoforms, namely human MT-IA and human MT-III (Figure 
3.7). Human MT-IIA, was found to have almost no inhibitory effect at any of the 
concentrations tested. This is in accordance with other MT-I/-II isoforms 
(recombinant rat MT-I/II, Erickson et al, 1994; recombinant mouse MT-I, Sewell et 
al, 1995). The inhibitory activity of sheep MT-III was found to be significantly 
smaller than human MT-III (p<0.01; student's t-test), which exhibited 22% and 53% 
inhibition at 1 [tg and 5tig/m1 respectively, similar to that reported previously 
(Erickson et al, 1994). 
3.4 Discussion 
3.4.1 Functional consequences of the altered protein structure of sheep MT-III 
Most of the proposed functions of MT are dependent upon the unusual 
structure of this protein. In particular, it is the presence of 20 conserved cysteine 
residues which are essential for MT's metal binding and redox characteristics. No 
significant variation in the number or relative position of these cysteines has been 
observed in previously isolated mammalian MTs (Kagi, 1993). Furthermore, MT-
III's neuronal inhibitory properties have been ascribed to the presence of a cysteine 
motif, C(6)PCP, present in the neural-predominant MT-III isoform, but not in other 
MTs (Erickson et al, 1994). 
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Figure 3.7: Rat cortical neurons were cultured with either 1 or 51..tg/m1 of human 
MT-IA, MT-III, or sheep MT-III, all in the presence of rat brain extract (150tig/m1). 
The percentage of growth inhibitory activity was calculated by the following 
formula: percentage inhibition = 100 — (100 x the number of neurons per field of 
view in the presence of added recombinant MT)/( the number of neurons in control 
cultures). * - p < 0.01; paired t-test. Error bars represent standard error values. 
Sheep MT-III has unique structural features compared to the previously 
characterised MT-III proteins and therefore may be useful in determining the 
physiological role of MT-III isoforms and their relationship to other MTs. The most 
striking feature of the sheep MT-III protein in comparison to any mammalian MT is a 
deletion of 3 amino acids (SCC) at positions 33-35. This is a deletion in the 
S(33)CC SCC (deleted amino acids are highlighted in bold) sequence that occurs 
directly after the 2 lysine residues which form the bridge between the a- and 13- 
domains of the MT protein. This sequence forms the start of the 13-domain of the 
protein, and is conserved among other mammalian MT protein sequences 
documented thus far (Bogumil et al, 1996). In earlier work (Holloway 1996, PhD 
thesis; Chung 1999, BSc Hons thesis), it was demonstrated that these changes were 
maintained in cDNAs from 12 individual sheep, representing two separate breeds 
(Merino and Pol Dorset). The number of cDNAs sequenced, in combination with 
Southern blotting, strongly suggested that only one expressed MT-III gene exists in 
sheep. In this chapter, it was demonstrated that the absence of these 3 cysteine 
residues has directly altered the metal binding properties of the sheep MT-III protein 
since the sheep isoform binds 5 zinc atoms per metallothionein molecule, whereas 
under the same conditions, human MT-III, and human MT-IIA bind seven. This is 
supported by Cismowski & Huang (1991), who found Chinese hamster MT mutants 
C( l 3)Y, C(50)Y and C(13)(50)Y  (in which cysteine 13, cysteine 50 or both cysteine 13 
and 50 are mutated to tyrosine residues) had metal-binding domains which tended to 
be folded less tightly and all three mutants bound 6 rather than 7 mole equivalents of 
cadmium. Furthermore, while some mutants retained their ability to protect against 
cadmium toxicity, others had reduced detoxification function (Cismowski & Huang, 
1991; Chernaik & Huang, 1991), and this would suggest that by analogy sheep MT-
III also has altered properties in vivo. 
3.4.2 Sheep MT-III exhibits neuronal growth inhibitory activity 
The neuronal growth inhibitory assay used in this chapter is based upon the 
assay used previously by Uchida et al (1991) and Erickson et al (1994). The basis of 
this assay is that the embryonic neurons are plated at a low cell density (5x10 4 
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cells/well) in serum-free culture media, which results in less than optimal culture 
conditions. To enhance survival, adult rat brain extract is added, in essence 
"rescuing" the neurons and it is against the action of this extract that the action of 
MT-III can be observed and quantified. Addition of recombinant human MT-III, in 
the presence of the brain extract, results in a significant decrease in neuron survival, 
hence exhibiting a neuronal growth inhibitory effect. Using this assay, it was found 
that recombinant sheep MT-III also exhibits inhibitory activity (13 and 37% 
inhibition; 1 and 5vg/m1 respectively), supporting the hypothesis first proposed by 
Sewell et al (1995) that the C(6)PCP motif, retained in sheep MT-III as well as the 
other known mammalian MT-III isoforms, confers this property. However, its 
growth inhibitory properties are not as potent as recombinant human MT-III (22 and 
53% inhibition; 1 and 5g/m1 respectively; p < 0.01; student's t-test, suggesting that 
perhaps other aspects of the physical structure of the MT-III molecule are intimately 
involved in its ability to inhibit neuronal growth. As an indication of this, Romero-
Isart et al (2002) have engineered the C(6)PCP motif found in MT-III into mouse MT-
I. While addition of the C(6)PCP motif alone into mouse MT-I did not confer 
inhibitory activity, introduction of the conserved T(5) residue found immediately prior 
to the C(6)PCP motif in native MT-Ills, to create the sequence T (5)CPCP, resulted in 
bioactivity. They concluded from their results that the structure/cluster dynamics of 
MT-III are critical for its neuroactivity. Interestingly, in sheep MT-III the T(5) 
residue is substituted with an A(5). Because threonine and alanine share similar 
physical characteristics, it is unlikely that this substitution would substantially alter 
the structural characteristics of sheep MT-III. However, the fact that sheep MT-III 
retains the C(6)PCP motif, yet exhibits reduced inhibitory activity, lends support to 
the suggestion of Romero-Isart and colleagues (2002) that the nature of the amino 
acid at position 5, and its effect upon the structure/cluster dynamics of the molecule, 
affects its growth inhibitory properties. However, it is also possible that other 
features specific to sheep MT-III, including other amino acid differences or even its 
altered metal binding properties, might be important in reducing its growth inhibitory 
ability. 
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3.4.3 Physiological significance of the evolutionary conservation of the C(6)PCP 
motif 
While sheep MT-III bears only 81% and 76% protein sequence homology 
with human and mouse MT-III respectively, it does retain the C(6)PCP motif common 
to all mammalian MT-III isoforms (but not found in any other MT isoforms). 
Furthermore, sheep MT-III also possesses the neuronal growth inhibitory properties 
conferred by this motif, although to a lesser extent. The fact that this motif is 
retained in all MT-III members characterized so far, including this unusual variant, is 
highly suggestive that this motif, and associated inhibitory activity, are an integral 
part of the physiological role of extracellular MT-III. While MT-III is considered a 
solely intracellular protein (Palmiter et al, 1992), Uchida et al (2002) have recently 
demonstrated that nanogram quantities of MT-III are actively released in culture by 
astrocytes, the primary cellular source of MT-III in the brain. Based on calculations 
that concentrations of MT-III in both rat and human adult brain range from 4-20m/g 
of brain (Erickson et al, 1994; Uchida et al, 2002), it is possible to envisage that 
extracellular levels of MT-III in the brain could feasibly reach the levels used in the 
work reported here (1-5 Rg/m1). Therefore, the hypothesis first raised by Uchida et al 
(1991) in the context of Alzheimer's disease that MT-III has an actual extracellular,, 
trophic role, presumably through modulating the aberrant reactive sprouting involved 
in neurofibrillary tangle formation, must remain a possibility. The following chapter 
continues this theme by precisely defining, for the first time, the action of human 
MT-III on neuronal growth and recovery from defined physical lesions. 
3.4.4 Susceptibility of sheep to heavy metal induced neurotoxicity 
It has been well documented that sheep are particularly prone to both 
deficiency (swayback disease; Alleyne et al, 1998; Howell et al, 1964) and 
overloading with dietary copper (chronic copper toxicity; Doherty et al, 1969). Both 
conditions, while initially affecting the liver and kidney, ultimately lead to dramatic 
neurological deficiencies, ranging from numerous lesions in the white matter 
(swayback; Tan & Ulrich, 1983) to severe swelling and vacuolation of the white 
matter and swelling of astrocytes (chronic copper toxicity; Doherty et al, 1969; 
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Morgan, 1973). The underlying biochemical mechanisms which lead to the 
neurological progress of these diseases is unknown, but it has been suggested that 
they may be caused by the miss-handling of copper in the brain. In light of the work 
reported here, it can be hypothesized that this might be related to the variant sheep 
MT-III protein, which has reduced metal binding capacity compared to other 
mammalian MT-Ills. It must be noted that MT-III knockout mice have been found to 
exhibit no apparent phenotypic changes up to two years of age (Erickson et al, 1997). 
However, sheep are much longer lived than rats, and unlike laboratory animals, sheep 
in agricultural situations are frequently exposed to environmental fluctuations in 
heavy metals such as copper. Thus, it may be• that sheep provide a model for 
revealing important physiological information on the role of MT-III. 
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Chapter 4: Investigation of the "neurite inhibitory" properties of human MT-III 
4.1 Introduction 
In the previous chapter, the neuronal growth inhibitory activity of human and 
sheep MT-III isoforms was evaluated using an assay first described by Uchida and 
colleagues (1991), which has become the standard means of measuring the inhibitory 
activity of MT-III (for instance, Erickson et al, 1994; Sewell et al, 1995). The basis 
of this assay is a low cell plating density of rat E 17-18 cortical neurons, which results 
-in culture conditions which are not optimal for cell survival. Addition of either an 
adult human brain or Alzheimer's disease brain extract to the neurons promotes 
survival over the three days of the assay, in essence "rescuing" the neurons. 
Subsequent addition of MT-III (either recombinant human or rat MT-III bound to 7 
zinc atoms per molecule) results in a significant decrease in neuron survival. As 
discussed by Uchida & Tomonaga (1989), this assay measures cell number either 
directly, or relative to accumulation of MAP-2, and hence is therefore an indicator of 
neuronal survival, rather than growth inhibition. However, Uchida et al (1991) 
further suggest that MT-III exhibits neurite growth inhibitory properties in culture, 
that is, that MT-III specifically inhibits the outgrowth of new neurites from newly 
plated embryonic neurons. However, this specific property has never, at the time of 
conducting the work described in this chapter, been reported within the literature by 
Uchida's group, or others. This is an important issue because the hypothesis that a 
deficiency of MT-III is involved in the abnormal sprouting thought to underlie the 
formation of the neurofibrillary tangles which characterize Alzheimer's disease, is 
based upon the putative neurite growth inhibitory properties of MT-III (Uchida et al, 
1991). In this regard, MT-III is often referred to as a neurite inhibitor, although as 
stated there is no evidence within the contemporary literature to support this 
contention. 
The aim of this chapter therefore is to investigate whether MT-III does indeed 
have neurite growth inhibitory properties, as opposed to its well documented effect 
on neuronal survival. This was performed in two different tissue culture models. In 
the first model, the effect of MT-III upon the early developmental processes of initial 
neurite formation and growth was investigated in single cell, embryonic cortical 
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neuron cultures similar to that established by Uchida et al (1989). In the second 
model, neurons were plated at a higher density, promoting the formation of neuronal 
clusters. By 21 days in vitro, these clusters form fasciculated axonal bundles 
between them, which can be transected (Dickson et al, 2000), and the effect of MT-
III upon the subsequent regenerative response can be examined. Because aberrant 
reactive sprouting is a possible process in the development of the neurofibrillary 
tangles seen in Alzheimer's disease, these experiments may elaborate the role that 
MT-III has in this disease. The final aim of this chapter was elucidation of the role 
that brain extract has in mediating MT-Ills activity, in light of previous reports that it 
is a necessary co-factor for observing MT-III's biological activity (Erickson et al, 
1994). 
4.2 Experimental Procedures 
4.2.1 Brief description of the low density neuron culture 
To maintain consistency, the culture conditions used within this chapter were 
based upon the neuron assay first described by Uchida et al (1991). The basis of this 
assay is a low cell plating density of rat E17-18 cortical neurons, which results in 
culture conditions which are not optimal for cell survival. Addition of either an adult 
human brain or Alzheimer's disease brain extract to embryonic rat cortical the 
neurons promotes survival over the three days of the assay, in essence "rescuing" the 
neurons. Addition of either recombinant human or rat MT-III (bound to 7 zinc atoms 
per molecule) results in a significant decrease in neuron survival. As an internal 
control for the experiments conducted in this chapter, recombinant human MT-IIA, 
bound to 7 zinc atoms, was used. Adult rat brain extract was used instead of human 
or AD brain extract due to availability issues. This was not expected to significantly 
alter the culture conditions however, as Uchida and colleagues have demonstrated 
that within their culture system, adult rat brain extract exhibits similar effects to 
human brain extract. 
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4.2.2 Low density neuron culture calculations and analysis 
For quantitative analysis of the effect of MT-III on initial neurite formation, 
10 bright field digital images from random areas of the coverslip were captured, for 
each timepoint, at a magnification of 400x (Olympus BL-51). Groups of three 
coverslips were used for each data point. Neuron viability was determined by trypan 
blue exclusion staining, and only viable cells were counted for all analyses. The total 
number of cells counted per coverslip ranged from 300-500 cells. 
The percentage of surviving neurons was determined by dividing the average 
number of neurons per field in the presence of MT-III (or vehicle treated) by the 
average number of neurons per field upon initial plating. Propidium iodide uptake 
was also performed to assess neuronal survival. 
Inhibition of neurite formation was investigated in two ways; the percentage 
of neurite-bearing neurons, and the number of neurites per neuron. A neurite (which 
includes both axons and dendrites) was defined as any process of at least 2011m 
extending from the cell body. The percentage of neurite-bearing neurons (or more 
accurately the percentage of neurons with one or more neurites) was calculated by 
dividing the average number of neurite-bearing neurons per field by the average total 
number of neurons per field. Of the neurite-bearing neurons, the number of neurites 
per cell was calculated by dividing the average number of neurites per field by the 
average number of neurite-bearing neurons per field. ANOVA, student's t-test and 
standard error analysis of results was made using SigmaStat (Jandel Scientific 
Software Corporation; San Rafael, CA). 
Neurite length measurements were manually performed using NIH Image 
analysis software, with at least 300 neurites being measured per treatment group. To 
determine the rate of neurite elongation between timepoints, the average length of 
neurites at the earlier timepoint was subtracted from the average length of neurites at 
the later timepoint. 
4.2.3 Neuron cluster culture calculations and analysis 
Cytoskeletal changes following axonal transection were identified by double 
labelling immunocytochemistry, using both anti-tau and anti-f3111-tubulin primary 
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antibodies. For analysis of tau/13III-tubulin immunolabeled coverslips at 12 hours 
post transection, 5 digital images of different injury sites of the coverslip were 
captured (Olympus BX-60). Each group, unless otherwise stated, consisted of at 
least 3 coverslips. All neurite measurements were performed using NIH Image 
analysis software. T-test and standard error analysis of results was made using 
S i gmaS tat. 
4.3 Results 
4.3.1 MT-III inhibits neuronal survival at high concentrations 
The objective of this chapter was to investigate whether human MT-III has a 
real neurite inhibitory ability, as opposed to its ability to inhibit neuronal survival 
which has been shown previously (Uchida et al, 1991; Erickson et al, 1994; Sewell et 
al, 1995). Therefore, to ensure that any neurite inhibitory effects of MT-III were not 
attributable to non-specific neurotoxicity, an experiment was conducted to establish 
the range in which no reduction in neuronal survival was observed. To determine 
such doses, a range of MT concentrations was applied to one day old neuron cultures 
in the presence of brain extract. The brain extract consisted of a homogenate of adult 
rat brain, which was applied to neuronal cultures at a concentration of 150m/m1 total 
protein. The percentage of surviving neurons was determined after a further three 
days in culture (Figure 4.1). At lower doses (0.01, 0.1 and 1tig/m1), MT-III had no 
significant effect on neuron survival, although the percentage of surviving neurons at 
all of these concentrations was lower than that of the vehicle (PBS) treated group. At 
the highest dose (5g/m1), MT-III had a significant inhibitory effect upon neuron 
survival, with survival reduced to 63% compared to 88% neuron survival in vehicle 
treated cultures (p < 0.01, student's t-test). These results were confirmed by 
propidium iodide uptake (Figure 4.1), which labels only dying cells. For subsequent 
studies investigating the neurite inhibitory properties of MT-III, levels which had no 
significant effect upon neuronal survival (0.1 and 1.0[4m1; less than 10% reduction 
in neuron survival compared to vehicle treated cells) were used. It must be noted that 
in these experiments human MT-III exhibited reduced inhibitory activity compared to 
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Figure 4.1: Human MT-III has a dose dependant, inhibitory effect upon neuronal 
survival in the presence of adult rat brain extract (equivalent to 150m/m1 protein). 
Neuronal survival was determined by direct cell counting and propidium iodide (PI). 
uptake. MT-III only significantly inhibited neuronal survival at 5!..tg/m1 (p <0.01, 
student's t-test). Error bars represent standard error values. 
those observed in Chapter 3 (3.3.4). However differences in the culture conditions 
could account for this. In Chapter 3, human MT-III was applied to neurons 
immediately upon plating, while in this chapter, human MT-III was applied one day 
post-plating. 
As a control, human MT-IA did not affect neuronal survival at up to 5m/m1 
dosages (results not shown), which is in accordance with other reported experiments 
using MT-I/-II isoforms (recombinant rat MT-I/II, Erickson et al, 1994; recombinant 
mouse MT-I, Sewell et al, 1995; Chapter 3, 3.3.4). 
4.3.2 MT-III inhibits neurite formation of developing cortical neurons 
To investigate the effect of MT-III on neurite development in culture, the 
process of initial neurite formation in the presence of MT-III was evaluated. Neurons 
were plated immediately in the presence of MT-III and adult rat brain extract, and 
maintained in culture for 3 days. MT-III clearly inhibited neurite formation of 
developing cortical neurons (Figures 4.2A, B), in a dose dependant manner (up to 
45% inhibition compared to vehicle treated by day 3, 1 p.g/m1 MT-III; Figure 4.2C). 
While these results demonstrate that there was a significant decrease in the number of 
neurite bearing neurons, MT-III mediated inhibition of neurite formation was not 
complete. Investigation of neurons with at least one neurite indicated that MT-III 
inhibited multiple neurite formation, with more than half of the neurons being 
unipolar, compared to the bipolar morphology of vehicle treated neurons (neurites 
per neuron values of 1.4 and 1.98 by day 3, 1g/ml MT-III and control cultures 
respectively; Figure 4.2D). Under similar conditions, MT-IA did not affect initial 
neurite formation, expressed as either the percentage of neurite bearing neurons, or 
the number of neurites per neuron (Figure 4.2E, F), suggesting that the observed 
effect of MT-III was not due to addition of recombinant MT per se, or its associated 
zinc ligands. 
To further investigate the effect of MT-III (11.tg/m1) on initial neurite 
formation, the previous experiment was repeated, but neurite formation was 
identified by immunocytochemistry, using a combination of anti-tau and anti-MAP-2 
primary antibodies. A number of neurites were noted, which were both tau and 
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Figure 4.2: The effect of human MT-III on neurite formation in the presence of adult 
rat brain extract (15Oug/m1) after 3 days (A — MT-III, B — vehicle; arrows indicate 
neurite bearing neurons) was determined by the percentage of neurite bearing 
neurons (C), and the number of neurites per neuron (D). MT-III significantly 
inhibited neurite outgrowth in both instances, at both concentrations tested (p <0.01, 
ANOVA). Error bars represent standard error values. 
—*--vehicle (PBS) 
--m— MT-11A (0.1pg/m1) 
—A—MT-11A (1pg/m1) 
- vehicle (PBS) 
—M— MT-11A (0.1pg/m1) 
—A—MT-11A (1pg/m1) 
0 	2 	4 	24 	48 	72 
time (hours) 
Figure 4.2: Human MT-IA had no effect on initial neurite outgrowth over 3 days, 
as assessed by both the percentage of neurite bearing neurons (E) or number of 
neurites per neuron (F). [p > 0.01, ANOVA] For all graphs, error bars represent 
standard error values. 
MAP-2 immunoreactive (Figure 4.3A), which has been reported previously (Kosik & 
Finch, 1987). It was apparent that the bipolar morphology of vehicle (brain extract 
only) treated neurons discussed previously is due to two tau immunoreactive 
processes, suggesting that these processes are precursors to axons. Analysis revealed 
that only 14% of all neurites were solely MAP-2 immunoreactive dendrites in vehicle 
treated neurons, but this was reduced to less than 3% following MT-III treatment 
(Figure 4.3B). This indicates that MT-III not only inhibits axonal formation (as 
noted by the unipolar morphology of neurons described previously), but also dendrite 
formation. 
4.3.3 MT-III delays neurite elongation of cortical neurons 
As noted above (Figures 4.2C, D), MT-III did not completely inhibit neurite 
formation. To investigate those neurites which were able to develop in the presence 
of MT-III, their rate of neurite elongation was measured. In the vehicle (PBS) treated 
group, there was an initial retraction by the neurites (between 0 and 2 hours), most 
likely in response to the medium change made in conjunction with MT-III addition 
(Figure 4.4A). From 2 hours onwards the rate of neurite elongation gradually 
increased, although there was a significant slowing of neurite elongation between 24 
and 48 hours, compared to 0-24 hours and 48-72 hours (p <0.01, student's t-test). 
In the presence of MT-III (both 0.1 and 1tig/m1) however, the initial retraction 
by the neurites, presumably in response to the medium change, was prolonged for an 
extra 2 hours (from 2 to 4 hours). Thus it would appear that MT-III delayed initial 
neurite elongation (between 2 and 4 hours). However, from 4 hours onwards there 
was no difference in the relative pattern of neurite elongation between vehicle (PBS) 
treated and MT-III neurites, although MT-III clearly reduced the absolute rate of 
neurite growth (Figure 4.4A). In the presence of MT-IIA (both 0.1 and 1[tg/m1), the 
rate of neurite elongation was significantly increased compared to control cultures 
(Figure 4.4B). 
The average total length of vehicle treated neurites at 3 days in vitro was 139 
± 3 IA m. MT-III significantly reduced average neurite length to 109 4t.tm  
(0.1 [A, g/m1) and 97 wn (1[1g/m1)(student's t-test, p<0.01; ± values represent 
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Figure 4.3: Immunocytochemistry of control (brain extract only) neuronal cultures to 
distinguish between axonal (tau) and dendritic (MAP-2) formation indicated a high 
degree of localisation of tau and MAP-2 in axons (A), as well  as several MAP-2 
immunoreactive dendrites (indicated by arrows). Following human MT-III 
treatment, there were significantly fewer, shorter axons, and no MAP-2 positive, tau 
negative dendrites (B). 
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Figure 4.4: Human MT-III prolongs the process of neurite retraction from 0-2 and 2- 
4 hours post plating (A), after which the rate of neurite elongation proceeds at a 
reduced rate. In contrast, human MT-IA significantly promoted the rate of neurite 
elongation (B). * - p <0.05; ** - p <0.01 (ANOVA). Error bars represent standard 
error values. 
standard error values). However, calculation of the average neurite length of MT-III 
treated neurons is misleading, as measurements were not normally distributed (ie: in 
a bell-shape distribution), and many MT-III treated neurites were much shorter than 
the actual average neurite length (Figure 4.5A). Hence, it is important to note that 
while MT-III significantly reduced the growth of the majority of neurites, a small 
number of neurites appeared to be unaffected by MT-III and actually grew to lengths 
comparable to those observed in vehicle treated cultures. 
Contrastingly, the average total length of MT-HA treated neurites at 3 days in 
vitro was 204 ± 101Am and 234 ± 10[Am (0.1 and lpg/ml MT-IIA respectively), which 
was significantly longer than vehicle treated neurites at the same time point (p<0.01, 
student's t-test). Furthermore, the distribution of MT-IIA treated neurites was also 
not normal, with many MT-HA treated neurites much longer than the average neurite 
length (Figure 4.5B). 
4.3.4 MT-III is not inhibitory in the absence of brain extract 
Previously, Uchida et al (1991) and Erickson et al (1994) have shown that 
MT-III inhibits neuronal survival in She presence of brain extract from normal 
humans, and brain extract from Alzheimer's disease sufferers. Furthermore, it was 
also demonstrated that, in the absence of brain extract, MT-III actually promoted 
neuronal survival in the embryonic cortical neuron culture assay (Erickson et al, 
1994). This suggests that MT-III is interacting with a constituent of the brain extract 
to inhibit neuron survival. To investigate whether MT-III can inhibit neurite 
outgrowth in the absence of brain extract, neurons were plated into medium 
containing either 1ia,g/m1 MT-III or PBS, all in the absence of brain extract. Analysis 
of the percentage of neurite bearing neurons (Figure 4.6A) and neurites per neuron 
(Figure 4.6B) after 3 days revealed that MT-III had no significant inhibitory effect 
upon initial neurite formation in the absence of brain extract. 
4.3.5 Elucidation of the specific interactions between MT-III and brain extract 
To begin to elucidate the factors within brain extract with which MT-III 
interacts, whole brain extract was fractionated by gel filtration using a Sephadex G- 
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Figure 4.5: The distribution of neurite lengths at 3 days post MT-III treatment (A) 
indicates that while MT-III significantly inhibited neurite growth, a small 
percentage of neurites were unaffected, and grew to lengths comparable to vehicle 
(brain extract only) treated neurites. The distribution of neurite lengths following 
MT-IA treatment indicated that a number of neurites grew to lengths greater than 
that of vehicle treated neurites (B). 
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Figure 4.6: MT-III does not exhibit neurite inhibitory properties in the absence of 
brain extract, either expressed as the percentage of neurite bearing neurons (A), or as 
the number of neurites per neuron (B). Error bars represent standard error values. 
75 column. An aliquot from each fraction was added to neuronal cultures at a protein 
concentration proportional to the contribution of that fraction to the original 150 
ug/ml protein supplied by the unfractionated brain extract, together with 1iug/m1 MT-
III, and neurite inhibition assessed relative to cultures that had received 
unfractionated brain extract and no MT-III. Two peaks were observed (Figure 4.7), 
indicating that MT-III is possibly interacting directly with more than one component 
of the brain extract. Based on calibration of the gel filtration column with a series of 
samples of known molecular weight, it was estimated that these two peaks 
correspond to approximately 150kD and 15-201cD. 
4.3.6 MT-III's inhibitory activity can be reversed 
Three days after MT-III addition (111g/m1) the culture medium was replaced 
with fresh medium (lacking MT-III), and brain extract, and the neurons incubated for 
a further 3 days. While neurite formation was inhibited in the presence of MT-III 
during the first 3 days (comparable to the results observed in Figures 4.2C, D), 
neurons were able to extend neurites following the medium change (as observed by 
the percentage of neurite bearing neurons and number of neurites per neuron; Figures 
4.8A and 4.8B respectively). Indeed, by 3 days post MT removal, the percentage of 
neurite bearing neurons was not significantly different to vehicle treated neurons 
(Figure 4.8A). This demonstrates that the effect of MT-III is reversible and suggests 
that MT-III is acting by a specific mechanism, rather than by a mechanism which 
involves reduction of neuron viability. 
4.3. 7 MT-III inhibits reactive neurite sprouting following axonal transection 
The previous experiments utilised a culture model which is well suited to 
quantitating the effect of MT-III on neurite development in relatively immature 
neurons. Recently, a more complex neuron culture model has been developed in this 
laboratory, which allows the investigation of the changes involved in reactive neurite 
sprouting which follows axonal transection to established clusters of mature (21 days 
in vitro) neurons in culture (Dickson et al, 2000). By analogy to the response seen in 
neurons in vivo following traumatic injury, the process of reactive neurite sprouting is 
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Figure 4.8: Inhibition of neurite formation by MT-III was reversed by replacing MT-
III containing medium with fresh medium which lacked MT-III. This was observed 
in both the percentage of neurite bearing neurons (A), and the number of neurites per 
neuron (B). The solid black bar represents the time in presence of MT-III. Error bars 
represent standard error values. 
interpreted as part of the subsequent regenerative process. To investigate the effect 
that MT-III has upon this neuritic response in culture, MT-III together with 150tig/ml 
of brain extract was applied to cortical neuron cluster cultures immediately after 
axonal transections. 
By 12 hours post transection in cultures that had received brain extract only, 
there was a marked retraction of the transected stumps from the lesion site (indicated 
by the broken line). Furthermore, there were a number of tau immunoreactive 
neurites identified extending from these transected stumps (Figures 4.9A, B). In the 
presence of MT-III (1 tig/m1) however, there was a reduction of over 50% in the 
number of tau immunoreactive sprouts (15.8 ± 1.3 sprouts/100ttm linear distance 
along the cut compared to 6.9 ± 0.9 sprouts/100ttm; p <0.01, student's t-test; Figure 
4.10A). Neurite length measurements indicated that the MT-III treated tau 
immunoreactive processes (mean neurite length = 15.9tim ±1.4tun) were 
significantly shorter than vehicle (PBS) treated processes (mean neurite length = 
41.5tim ±1.711m) at this time point (p < 0.01, student's t-test; Figure 4.10B). In 
comparison, in the presence of MT-HA (11,1g/m1), a number of reactive processes 
were identified extending from the transected stumps (Figures 4.9C, D). Quantitative 
analysis indicated that there were more reactive sprouts compared to the vehicle (20.8 
± 0.8 vs 15.8 ± 1.2; p = 0.07, student's t-test; Figure 4.10A), and that these processes 
were significantly longer (mean neurite length = 70.1pm ±3.4t.tm vs 41.5Rm ±1.7tim; 
p < 0.01, student's t-test; Figure 4.10B). By 18 hours post transactions, MT-HA 
treatment had promoted the growth of reactive sprouts across the entire transection 
tract, which was not observed following vehicle or MT-III treatment (Figure 4.11). 
4.4 Discussion 
4.4.1 MT-III is a specific inhibitor of initial neurite formation in culture 
Human MT-III significantly inhibited initial neurite formation, as assessed by 
both the percentage of neurite bearing neurons, and the number of neurites per 
neuron. This was observed with concentrations of MT-III that did not significantly 
reduce neuronal survival (less than 10% reduction in neuronal survival compared to 
vehicle treated neurons). Propidium iodide studies confirmed that these levels of 
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Figure 4.9: Fluorescent double immunocytochemical labeling of cytoskeletal 
changes, both tau (red) and PIII-tubulin (green), 12 hours after axonal transection (A, 
B). Treatment with MT-III (11.t.g/m1; C, D) reduced regenerative neurite sprouting 
compared to vehicle treated. The transection site is indicated by  the broken line, and 
there is a large area of retraction away from this line. Sprouting neurites are 
indicated by arrows. MT-IA treatment increased both the number and length of 
reactive sprouts following injury (E — vehicle, F — MT-IA, 1 ttg/m1). Scale bars 
represent 60ium (A, C, E, F) and 30iim (B, D). 
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Figure 4.10: Treatment with human MT-III significantly inhibited both the number 
(A) and length of reactive sprouts (B) at 12 hours post- axonal transection in culture. 
However, human MT-IA significantly increased the mean neurite length of reactive 
sprouts (B). * - p<0.01, (paired t-test). Error bars represent standard error values. 
Figure 4.11: Fluorescent double immunocytochemical labeling of cytoskeletal changes, both tau (red) and 13III-tubulin (green), 18 hours after 
axonal transection. MT-HA promoted reactive axonal growth across the entire transection site (A), which was not observed following treatment 
with either vehicle (B) or MT-III (C). scale bars: A = 100Rm; B, C = 50gm 
MT-III were not significantly toxic at up to 6 days post MT-III treatment. This is in 
accordance with a report, which was published following the completion of the work 
discussed in this chapter, that also indicates that MT-III inhibits initial neurite 
extension of cortical neurons in culture (Uchida et al, 2002). Furthermore, the 
inhibitory activity of MT-III was reversible, suggesting that MT-III is a specific 
inhibitor of initial neurite formation and growth. To account for the possibility that 
zinc (released from MT-III) or an artifact from the recombinant protein purification 
process was responsible for the observed results, experiments were also conducted 
with another recombinant human MT isoform, MT-IIA (also bound to 7 zinc atoms 
per molecule). MT-IA did not alter the initial formation of neurites, but surprisingly 
significantly accelerated the rate of neurite elongation. Furthermore, MT-IA also 
significantly promoted recovery following axonal transection. These unexpected 
properties of MT-IIA will be discussed further in Chapter 5. These results suggest 
that MT-III is a true neurite inhibitor, separate from its ability to inhibit neuronal 
survival. 
4.4.2 The role of brain extract in MT-III mediated neurite inhibition 
The absence of any inhibitory activity of MT-III when brain extract was not 
applied to cultures indicates that adult rat brain extract contains a necessary co-factor 
for the neurite inhibitory activity of MT-III, or that it is inhibiting a neurite growth 
promoting molecule present within brain extract. Further experiments suggested the 
possibility of MT-III interacting with more than one component of brain extract, as 
evidenced by MT-III induced reduction in neurite outgrowth in the presence of two 
different fractions obtained from gel filtration of whole brain extract. Based upon 
calibration of the column with samples of known molecular weight, the brain extract 
fractions correspond to sizes of approximately 1501d) and 15-201cD. The 15-201d3 
size range is of particular interest, as this is the size range of many neurotrophic 
factors such as neurotrophins (Bibel & Barde, 2000). Indeed, a possible mechanism 
for protein-protein interaction between MT-III and another protein has been recently 
described by Oz et al (2001). They report that the acidic insertion to the alpha-
domain of MT-III (relative to all other MT isoforms) is accommodated within a loop, 
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which exhibits dynamics identifying it as a possible interaction site with other 
proteins (See Chapter 1.4.2). As further evidence of the potential interactions 
between MT-III and other molecules, several reports suggest that MT can bind ATP 
under physiological conditions (Maret et al, 2002; Jiang eta!, 1998). Interestingly, it 
has been demonstrated that inosine, the breakdown product of ATP, is capable of 
promoting significant neurite growth in culture and in vivo (Benowitz et al, 1999, 
2002). Because inosine is the major break-down product of ATP, it is possible that 
any ATP released from lysed cells during the production of brain extract will 
accumulate as inosine. In this regard, it is feasible to envisage that MT-III may bind 
to inosine, in essence titrating it out of the brain extract, to exhibit its neurite 
inhibitory activity. This specific hypothesis can be readily tested in further work. 
To further identify the potential binding partners of MT-III within brain 
extract, classical pulldown assays could be performed, by biotinylating MT-III and 
binding the conjugate to strepdavidin bound Dynabeads. Bound substrates would be 
analysed by SDS-PAGE and mass spectrometry. 
4.4.3 MT-Ill in neurological disorders 
An exciting potential role for MT-III was suggested by its apparent deficiency 
in the Alzheimer's disease brain, and the idea that this deficiency was a causative 
factor in the development of neurofibrillary tangles (Uchida et al, 1991). However, 
reports of MT-III levels in the AD brain are conflicting, with findings of both 
deficiency (Uchida eta!, 1991; Tsuji et al, 1992; Yu et al, 2001) and no deficiency 
(Erickson et al, 1994; Carrasco et al, 1999). While this issue is clouded, there is 
separate biochemical evidence for a link between MT-III and AD. For instance, 
oxidative stress has been implicated in the neuropathy of AD (Hensley et al, 1994), 
and thus a deficiency in MT-III, a known free radical scavenger in vitro, may be 
involved in the development of AD. It has also recently been reported that MT-III 
can inhibit the formation of neurotoxic ilamyloid aggregations in vitro (Irie & 
Keung, 2001), and protect against free radical damage induced by the 13-amyloid 
peptide 25-35 (Ren et al, 2001). The observation here that MT-III inhibits tau 
immunoreactive neurite sprouting (hypophosphorylated tau is the major constituent 
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of NFTs) indicates that a deficiency in MT-III in the brain could indeed be a possible 
mechanism involved in NFT formation. 
MT-III may also have a role to play in other neurological disorders. For 
instance, the fact that MT-III null mice are highly susceptible to kainic acid seizures 
(Erickson et al, 1997) suggests that MT-III is involved in the pathology of epileptic 
seizures. Indeed, MT-III over-expressing mice exhibit much less kainic acid induced 
brain damage than control mice (Campagne et al, 1999). It is possible that the zinc 
binding properties of MT-III would allow it to regulate electrically stimulated 
synaptic zinc release, preventing possible seizure occurrence. However, Cole et al 
(2000) using ZnT3/MT-III double knockout mice (which lack vesicular zinc) have 
concluded that MT-III is unlikely to protect against kainic acid induced seizures by 
modulating intracellular zinc release. Interestingly, McKinney et al (1997) have 
reported abnormal neurite sprouting following axonal injury to CA3 hippocampal 
neurons in brain slice culture (one of the most MT-III rich regions in the brain). 
Furthermore, these injured pyramidal neurons were hyperexcitable, and synaptic 
responses often displayed unusual prolonged polysynaptic components. Hence, it 
may be that MT-III protects against seizures by preventing abnormal neurite 
sprouting following axonal injury. 
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Chapter 5: Human MT-HA promotes reactive neurite sprouting and 
cortical wound healing 
5.1 Introduction 
During the investigation of the neurite growth inhibitory properties of human 
MT-III described in the previous chapter, it was surprisingly found that human MT-
HA exhibited different neuroactive properties when applied to cultured cortical 
neurons. That is, MT-IA significantly promoted neurite elongation (but not initial 
neurite formation), and also promoted reactive axonal sprouting and growth 
following injury in vitro. At about the same time that this work was performed, 
several reports indicated a correlation between the presence of MT-I/-II and the 
ability of animals to recover from a variety of brain lesions. These were based 
primarily upon studies utilising transgenic knockout MT-I/-II mice, which exhibit 
dramatically reduced ability to recover from cortical cryolesion injury (Penkowa et 
al, 1999a) and focal cortical ischaemia (Campagne et al, 1999). Furthermore, these 
animals exhibited significant impairment of glial cell responses to injury, which 
resulted in changes at the molecular level including reductions in cytokine expression 
(such as IL-1, IL-6 and TNF-a; Penkowa et al, 1999b). Neuronal apoptosis was also 
significantly increased in the MT-I/-II knockout mice. Based on these results, 
Penkowa et al (1999b) proposed the hypothesis that the protective effect of MT-I/-II 
involves glial cell activation and reduction of post injury inflammation. Surprisingly, 
some neuroprotective activity was also observed when Zn-MT-II was 
intraperitoneally given to MT-I/-II knockout mice (Penkowa et al, 2002), indicating 
that MT may be acting by a previously unsuspected, extracellular mechanism. 
Based upon the results of Chapter 4 which suggest an ability of MT-IA to 
promote reactive neurite sprouting and regeneration following injury in culture, it 
was hypothesised that the neuroprotective properties of MT-I/-II observed previously 
might be due to a direct action of MT-IA on neurons, in addition to the proposed 
action of MTI/II on glial cells and the CNS cytokine profile (Penkowa eta!, 1999b). 
This possibility has not been identified by Penkowa and colleagues since the main 
focus of their work has been on glial cells and cells of the CNS immune system, and 
to date they have not reported an extensive investigation of the neuronal response to 
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injury of exogenous metallothionein. Hence, the aim of this chapter was to 
investigate the neuronal response to rat cortical brain injury following recombinant 
human MT-IA treatment. The injury model used was a focal cortical needle stick 
injury model, which has been well characterised in this laboratory (King et al, 1997; 
2001). In particular, temporal profiles for changes in glial cell activation and 
migration, and reactive neurite sprouting have been characterised for this model. 
These changes are observed immunohistochemically using antibodies against ferritin 
(activated microglia), GFAP (astrocytes) and SMI-312 (a cocktail of antibodies 
directed against phosphorylated neurofilaments, which are found only in axons). 
5.2 Experimental Procedures 
5.2.1 Cortical brain needle stick injury analysis 
Focal cortical brain injuries were performed on 250g male adult rats, using a 
brain injury model developed previously in this laboratory (King et al, 1997; 2001), 
and described in detail in Chapter 2 (2.4.1). MT-IA was applied to the lesion site (in 
gelfoam placed directly above the lesion; 10Ong total MT-IA in 20111 PBS) following 
cortical needle stick injury. For analysis of tissue sections, digital images were 
captured using the Olympus BX-60 digital camera (Olympus BL-51 microscope). A 
total of 16 rats were treated with MT-IA (in 4 different experiments), and 
maintained for 4 days post injury. The same number of control animals (treated with 
PBS) were also used. A further 12 rats received MT-IA (in 4 different experiments) 
for 7 days post injury studies, and a similar number of animals received vehicle 
(PBS). All measurements were performed using NIH Image. T-test analysis was 
performed using SigmaStat (Jandel Scientific Software Corporation). 
The volume of tissue exhibiting ferritin immunoreactivity was used as a 
measure of inflammatory response. The volume of the inflammatory response to 
injury was determined from the area of ferritin immunoreactivity in the epicentrical 
tissue section, and the next two consecutive sections in either direction. The 
percentage of tissue degradation was determined by subtracting the area of empty 
space from the total area of ferritin immunoreactivity within a brain section. For both 
of these analyses, 9 animals (over 3 different experiments) were used. 
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5.2.2 Protein isolation from gel foam, SDS-PAGE and western blotting 
Absorbant gel foam, which had been used to seal the burr hole in the skull 
during the initial surgery, was recovered at a variety of time points post-injury (3 
animals per group). Soluble proteins were removed from the gel foam by the 
addition of 100[1.1 of PBS, followed by vortexing. Crude gel foam extracts were 
examined by Western blotting analysis, as discussed in Chapter 2. 
5.3 Results 
5.3.1 NIT-HA promotes wound healing and reactive axonal growth following 
cortical brain injury 
To investigate the effect of human MT-IA upon wound healing and reactive 
cytoskeletal changes following brain injury in the rat, MT-IA was applied to the 
lesion site (as discussed in 5.2.1) following cortical needle stick injury. At 4 days 
post injury in vehicle (PBS) treated rats, the area of the injury site was clearly 
demarcated by ferritin immunoreactivity (Figure 5.1A). The volume of inflammatory 
response (defined by ferritin immunoreactivity) was not significantly affected by 
MT-IA application (p = 0.096, student's t-test), although the volume in all MT-IA 
animals (average volume = 2035 ± 54= 3) was smaller than vehicle treated rats 
(average volume = 2772 ± 78mm 3). From the pial surface down, MT-IA treatment 
resulted in the formation of a cellular bridge enclosing the injury site, resulting in a 
teardrop-like injury site (Figure 5.1B). The percentage of tissue degradation within 
the area of inflammation was significantly greater within vehicle treated animals 
(54% ± 4 vs 12% ± 11; p<0.01, t-test). 
MT-IA promoted the growth of a number of SMI-312 immunoreactive 
axonal processes into the injury site, at all cortical levels injured, as well as at the pial 
surface (Figures 5.1C, D). This was in marked contrast to vehicle treated rats, in 
which very few SMI-312 immunoreactive processes were visualized entering the 
lesion site (Figures 5.1E, F). As reported previously, these SMI-312 immunoreactive 
reactive axonal sprouts exhibited a higher degree of labeling for neurofilaments than 
adjacent, uninjured processes (King eta!, 2001). 
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Figure 5.1: Immunohistochemistry for SMI-312 (green; axonal marker) and ferritin 
(red; microglial marker) at 4 days post injury. Needle stick injury resulted in a large 
injury tract, and microglial migration into and surrounding the injury site (A). MT-
IA treatment promoted the formation of a tissue bridge enclosing the lesion site from 
the pial surface down, forming a teardrop like invagination (B). MT-IA promoted 
axonal sprouting into the lesion site at both the pial layer (C) and deeper cortical 
layers (D). In contrast, very few axonal sprouts were visualised in control rats, at the 
pial level (E) or deeper cortical layers (F). Arrowheads indicate the injury tract. 
scale bars: A, B = 100Rm; C-E = 251.tm 
By 7 days PI in vehicle treated rats, the injury tract was significantly smaller 
than at 4 days PI, although a cavity was often evident (Figure 5.2A). Reactive 
sprouting was observed in all vehicle treated animals at this timepoint (Figure 5.2A). 
Reactive astroglial migration resulted in a thick line along the borders of the injury 
tract, and reactive astrocyte density gradually diminished away from the injury site 
(Figure 5.2B). In MT-IA treated rats, the entire injury tract was enclosed. 
Microglial inflammation was decreased, and was found as a thin line of ferritin 
immunoreactive cells demarcating the injury site (Figure 5.2C). Astrocytes also 
formed a thin line marking the injury tract. The density of reactive astrocytes 
decreased further from the injury site (Figure 5.2D). Numerous SMI-312 
immunoreactive processes were observed within the injury tract, although these 
processes often did not exhibit a higher degree of labeling than neighbouring, 
uninjured processes (Figure 5.2E). At the pial surface however, long reactive axonal 
processes were observed entering the injury site, which exhibited increased labeling 
compared to adjacent, uninjured processes (Figure 5.2F). 
5.3.2 Western blotting analysis of endogenous MT-I/-11 following cortical brain 
injury 
The previous experiments examined the effect of exogenous human MT-IA 
on recovery from cortical lesions; however, it is possible that the treatment with 
recombinant MT-IA is acting over and above that mediated by endogenous MT-I/-II. 
As a first step to investigate this, studies by Paul Adlard within this laboratory have 
demonstrated that MT-I/-II is indeed induced in the vicinity of this type of cortical 
injury. While MT-I/-II immunoreactivity was not evident in normal un-injured 
neocortex, MT-I/-II labelling was significantly up regulated by 7 days PI, decreasing 
by 14 days PI (Adlard, 2000, PhD thesis). MT-I/-II immunoreactivity was confined 
to astrocytes, and MT-I/-II positive astrocytes were often observed aligned along the 
injury tract (Figure 5.3). Intriguingly, MT-I/-II immmunoreactivity was maximal at 
the same time that reactive sprouting is observed within this animal injury model 
(King et al, 1997; 2001). This suggests that in analogy to the ability of MT-IA to 
promote reactive axonal sprouting, endogenous MT-I/-II might be acting to directly 
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Figure 5.2: Immunohistochemical staining against SMI-312 (green), ferritin (red) 
and GFAP (black and white images; astrocytic marker) of brain sections at 7 days 
post injury. In vehicle treated rats, the injury tract was smaller compared to 4 days 
post injury, although it had not completely closed over. A degree of reactive 
sprouting was evident (arrows) in all animals at this timepoint (A). Reactive 
processes exhibited greater SMI-312 reactivity than background neuritic processes. 
Reactive astrocytes also aligned along the borders of the injury tract (B). In MT-IA 
treated rats, the entire injury tract had closed over, and was demarcated only by a fine 
line of ferritin immunoreactivity (C). Reactive astrocytes also enclosed the injury 
tract, and were found at lower density in adjacent uninjured tissue (D). In MT-IA 
treated animals, numerous reactive axonal processes were observed (arrows) within 
the injury tract, at both deeper cortical levels (E) and the pial level (F). scale bars: A 
= 501.1m; B-D = 100Rm; E, F = 251.km 
Figure 5.3: Immunohistochemical analysis following focal cortical brain injuries. At 
one day post-injury (PI), MT-I/-TI labelling is absent (A). Arrows indicate the 
location of the needle tract. At four (B) and seven (C) days PI, MT-I/-II 
immunoreactivity is localised to glia-like cells (arrowheads), cells and processes 
surrounding blood vessels (arrows in B), and processes along the pial surface (arrow 
in C). At 7 days PI (confocal microscopy, D) cells labelled for MT-I/-II (green; 
arrowheads) have a cell body and/or processes labelled for GFAP (red). The pial 
surface is indicated (arrow). In contrast, at the same time, ferritin immunoreactive 
microglia (E; red) are not co-labelled for MT-I/-II (green). The border of the needle 
tract is indicated (arrow). Modified from Adlard, 2000, PhD thesis. 
promote neuronal recovery. To investigate whether endogenous MT-I/-II is present 
extracellularly following cortical brain injury, the gel foam overlying the lesion (in 
vehicle treated animals) was recovered following injuries, and the crude gel foam 
extract analysed by western blotting. MT-I/-II immunoreactivity was observed at 
both 7 and 14 days PI (Figure 5.4). Re-probing of blots for ferritin and GFAP did not 
exhibit immunoreactivity, suggesting that there were not significant numbers of 
either astrocytes or microglia present in the gel foam. 
5.4 Discussion 
5.4.1 MT-HA promotes wound healing and reactive axonal growth following 
cortical brain injury 
Exogenous application of human MT-IA following cortical brain injury in 
rats significantly promoted wound healing. This was observed by the rapid closing 
over of the injury tract by 7 days PI, as well as the presence of numerous reactive 
processes bridging the injury tract. In previous studies using this model, which did 
not include MT administration, it has been noted that it requires up to 21 days PI for 
the injury tract to become almost indistinguishable from surrounding, un-injured 
cortical tissue (King et al, 2001). Hence, it appears that MT-IA application has 
accelerated the wound healing process. To quantitatively assess the effect of MT-IA 
upon reactive neurite sprouting, brain tissue from the injury tract could be collected 
and western blotting performed for SMI-312 immunoreactivity. Measurement of 
band intensity between vehicle and MT-IA treated animals would provide 
quantitative evidence that MT-IA promotes reactive sprouting into the injury tract. 
Based upon these results and those discussed in Chapter 4, it is possible that 
the previously reported ability of MT-I/-II to promote cortical wound healing 
(Penkowa et al, 1999a; Campagne et al, 1999) could be attributed to two distinct 
mechanisms. Firstly, work by other groups suggests that MT-I/-II is essential for a 
number of post-injury recovery processes, such as astrocytic activation and 
migration, as well as decreasing inflammatory responses (such as microglial 
activation and pro-inflammatory cytokine expression). Indeed it was noted in the 
54 
• 
•. 05. • . „, • 
r 
• 
1 
• 
4O1111. ale 
3. 	4. 	5. 
Figure 5.4: Western blotting analysis of protein extracted from gel foam recovered 
from cortical brain injury sites, using antibodies against MT-I/-II (A), ferritin (a 
marker of activated microglia; B) and GFAP (a marker of astrocytes; C). Lanes 
contained the following: 
Lane 1 — gel foam extract, 1 day post injury (PI) 
Lane 2 — gel foam extract, 4 days PI 
Lane 3 — gel foam extract, 7 days PI 
Lane 4 — gel foam extract, 14 days PI 
Lane 5 — crude brain homogenate of an area of tissue encompassing the injury 
site at 7 days PI. This tissue acts as a positive control, as all three 
antigens are expected to be present within this sample. 
A 
work presented here that there was clearly a reduced inflammatory microglial 
response at 4 days PI following MT-IA treatment. And secondly, based upon both 
the results within this chapter and that of the previous chapter, MT-I/I may also 
promote cortical wound healing by acting directly upon neurons to promote neural 
recovery. Both of these mechanisms appear to be generic to the MT-I/-II isoforms, 
as similar results have been observed with a commercial source (results not 
shown; rabbit mixed Zn-MT-I/-II, Sigma). 
To define the relative contribution of the direct effect of MT-IA upon 
neurons as opposed to their proposed ability to suppress immune response in the 
injured brain environment, a series of experiments could be conducted in animals 
with a compromised immune system. One such experiment would be to assess the 
ability of MT-IIA to enhance recovery from lesions in cyclosporine A treated rats. 
The use of a rat model is advantageous since it will allow reference to our previous 
work. While cyclosporine A has been demonstrated to have a small effect upon 
neurite extension and sprouting (Sugawara et al, 1999), based upon the significant 
effect of MT-IA administration to lesioned rat cortex, it would be expected that MT-
IA treatment woud result in a quantifiable difference over and above that due to 
cyclosporine A alone. MT-IA could also be tested in nude mice, which lack a 
competent immune system. While MT-IA has not been administered to mouse 
models in this laboratory to date, based upon an extensive literature including MT 
knockout- and over expressing- transgenic mice, it seems feasible that similar results 
to those observed in rats would be expected. 
It has been demonstrated within the literature that the pro-inflammatory 
cytokine interleukin-6 (IL-6) mediates MT-I/-II induction by inflammation, through 
its responsive transcription factor Stat3 (Hernandez et al, 2000). Intriguingly, it has 
been recently reported that IL-6 may also have an important role in plasticity and 
regeneration, which is separate from its role in the inflammatory response associated 
with brain injury (Parish et al, 2002). Briefly, Parish and colleagues (2002) 
demonstrated the lack of reactive sprouting following injury to the substantia nigra 
pars compacta in IL-6 knockout mice. Additional reports, both in culture (Schafer et 
al, 1999) and in vivo (Shuto et al, 2001), support the notion that IL-6 is able to 
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directly promote neurite regeneration. This suggests that both IL-6 and MT-I/-II 
have dual functional roles within the brain following injury, whereby they act 
initially in an inflammatory role, followed later by a role in plasticity and 
regeneration. In this regard, these proteins probably act in a differential temporal 
profile to promote neuronal recovery, as IL-6 (together with a number of other 
inflammatory cytokines) is rapidly expressed in response to cortical brain injury (Yan 
et al, 1992), and decreases coincident with the increased expression of MT-I/-II 
(Penkowa et al, 1999b have demonstrated that MT-I/-II can suppress IL-6 
expression) which occurs several days after the original injury (Adlard, 2000, PhD 
thesis). 
A limitation of the experimental injury model used within this chapter is that 
functional recovery cannot be assessed. In this regard, alternative experimental 
models may be more effective in evaluating the ability of MT-I/-II to promote 
neuronal recovery following injury. One possible model is experimental spinal cord 
injury. In parallel to cortical brain injury, MT-I/-II are significantly up-regulated 
following injury to the adult rat spinal cord (Carmel et al, 2001), indicating the 
potential involvement of these proteins in the cellular response to such injury. 
Furthermore, a number of tests have been devised to assess the functional recovery of 
animals following a variety of different models of spinal cord injury (as reviewed by 
Schwab & Bartholdi, 1996). Perhaps a future challenge will be to investigate 
whether MT-IA is able to promote neural recovery in complex injury paradigms 
such as spinal cord injury. 
5.4.2 Release of endogenous MT-IMI in response to neuronal injury 
Work in our laboratory by Adlard (2000, PhD thesis) has shown that the 
cortical injury model used here is characterised by a dramatic upregulation of MT 
about 4 days after the lesion. Interestingly, it was found here that endogenous MT-I/-
I! was detectable within gel foam retrieved following rat brain injuries in vehicle 
treated animals, in the absence of astrocytes and microglia, suggesting that this MT-
I/-II is extracellular. It is possible that these two observations are related, that is, the 
extracellular MT recovered from the gel foam is actually released by the reactive 
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astrocytes surrounding the lesion. One alternative suggestion is that the detected 
MT-I/-II is released from dying astrocytes rather than through an active release 
mechanism. Preliminary work performed concurrently to this thesis by Justin 
Dittmann indicated that MT-I/-II may be actively released from cultured astrocytes 
following induction by zinc (Dittmann, 2002, BSc hons thesis). These results support 
those in the literature reporting the detection of MT-I/-II in the extracellular 
environment in vivo (Bremner et al., 1987; Garvey, 1984; Hidalgo et al., 1988), and 
in culture (Trayhurn et al., 2000). Based on these results, it is therefore hypothesized 
that the extracellular neuroactive properties of MTs discussed within this thesis occur 
physiologically within the brain. If so, this implies that the exogenous human MT- . 
IIA is able to promote reactive sprouting over the top of endogenous MT-I/-II. One 
possibility is that human MT-IA is more effective than the endogenous rat MT-I/-II 
isoforms at promoting neuronal recovery. However, based on protein sequence 
alignment, there is very little difference in the structure of these proteins (Figure 5.5). 
An alternate possibility is that exogenous MT-IA stimulates astrocytes surrounding 
the injury tract to up-regulate endogenous MT-I/-II at greater levels, or in a different 
temporal timeframe in comparison to untreated animals. Another possibility is that 
exogenous MT-IA accelerates repair processes when it is applied acutely after 
injury, in contrast to endogenous MT-I/-II which is not observable until 4 days after 
the original injury (Adlard, 2000, PhD thesis). 
5.4.3 The possible physiological role of endogenous MT-V-II following brain 
injury and in neurodegenerative diseases 
It is well documented that MT-I/-II expression is up-regulated not only in 
response to a number of different models of experimental brain injury to the rat 
(including focal injury, freeze lesion and ischaemia; see review by Hidalgo et al, 
2001), but also a number of neurodegenerative disorders including Alzheimer's 
disease, EAE (an animal model of multiple sclerosis) and familial amyotrophic 
lateral sclerosis. The general consensus is that this is in response to oxidative stress 
or to elevated cytokine levels, a downstream by-product of cellular injury. However, 
it is also possible to hypothesise that the up-regulation of endogenous MT-I/-II is 
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Figure 5.5: The protein sequences of human MT-IA, rat MT-I and rat MT-II were 
aligned to identify structural differences. Amino acids which vary between human 
MT-IA and either rat MT-I or rat MT-II are indicated by asterisks, while amino 
acids which are different to both rat isoforms are highlighted in boxes. 
directly induced by neuronal injury as a post-injury regenerative response, which has 
evolved to specifically protect neurons, and to enhance regenerative sprouting, and 
which involves an extracellular component of action as suggested by the work in this 
chapter. As an indication of this, expression peaks at 7 days PI within the 
focal cortical injury model used within this chapter, which coincides with the 
appearance of reactive axonal sprouts entering the injury tract (Adlard, 2000, PhD 
thesis). To further explore this hypothesis, neuronal/astrocyte co-cultures were 
established, to attempt to generate a model in which neuronal-astrocyte interactions, 
possibly involving metallothionein induction and release, can be observed in the 
presence or absence of injury. These experiments will be presented in the next 
chapter. 
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Chapter 6: Investigation of astrocytic expression of MT-IMI in a 
neuron/astrocyte co-culture model 
6.1 Introduction 
In the previous chapter, it was demonstrated that endogenous MT-I/-II is 
present in the extracellular environment following cortical brain injury. An exciting 
possibility is that, analogous to the ability of human MT-IA to promote reactive 
sprouting in culture, endogenous MT-I/-II is able to directly promote neuronal 
recoveiy following injury in vivo. Interestingly, there is considerable literature 
indicating that MT-I/-II are up-regulated in response to various other experimental 
models of brain injury, including cryolesion, chemical induced injury and 
experimental autoimmune encephalomyelitis (for review, see Hidalgo et al., 2001). 
Furthermore, numerous reports indicate an up-regulation of MT-I/-II within 
astrocytes in a number of neurodegenerative disorders, ranging from early stages of 
Alzheimer's disease (Adlard et al, 1998), to amyotrophic lateral sclerosis (Gong & 
Elliott, 2000). Taken together, this evidence is highly suggestive that MT-I/-II are 
involved in the cellular response to neuronal injury. 
Based on the work of Hidalgo and colleagues, proinflammatory cytokines 
such as IL-6 and TNF-a are important inducers of MT-I/-II expression following 
brain injury. They have demonstrated that in both IL-6 and TNF-a knockout mice, 
there is a dramatic deficit in MT-I/-II response to brain injury (Carrasco et al, 1998; 
Penkowa et al, 2000). This is in accordance with tissue culture experiments that 
report the induction of MT-I/-II by a number of inflammatory cytokines (Coyle et al, 
1995). 
An intriguing observation in our laboratory is that the up-regulation of MT-I/- 
II by astrocytes observed either following cortical brain injury (Adlard, 2000, PhD 
thesis) or in the pre-clinical Alzheimer's brain (Adlard et al, 1998) is not uniformly 
distributed. That is, while all MT-I/-II immunoreactive cells and processes co-
localise for GFAP positive astrocytes, not all GFAP immunoreactive astrocytes are 
MT-I/-II positive. This suggests that the induction of MT-I/-II expression in response 
to brain injury might not be solely attributable to cytokines. Based on this, the 
primary aim of this chapter was to try and elucidate mechanisms other than 
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inflammation related molecules such as cytokines, which could contribute to the 
changes in MT-I/-II expression observed following brain injury, using tissue culture 
techniques. 
6.2 Experimental Procedures 
6.2.1 Brief description of neuron/astrocyte co-cultures 
As discussed in Chapter 2.3.3, neuron/astrocyte co-cultures were obtained 
from cortical tissue from embryonic day 19 (sperm positive day = El) rat embryos, 
using a method modified from that reported by Schlag et al (1998). Two types of co-
culture were maintained, either neuron enriched (more than 50% neurons) or 
astrocyte enriched (more than 50% astrocytes). Neuron enriched co-cultures were 
obtained by performing a full medium change every three days, while astrocyte 
enriched co-cultures were obtained by performing a half medium change once a 
week. 
6.2.2 Analysis of MT-I/-II immunoreactivity 
For analysis, 25 digital images were taken from 3 coverslips per group. In the 
case of coverslips with scratch wounds, images were captured aligning the injury 
tract. All images within an individual experiment were captured at the same 
exposure time at 400x magnification. Furthermore, all coverslips within an 
individual experiment underwent immunocytochemistry at the same time. 
Experiments, unless otherwise stated, were performed in triplicate (that is separate 
cultures derived from fetuses from three different pregnant rats). Changes in MT-I/- 
II expression were qualitatively determined by mean intensity values, using a method 
based on that of Levadoux and colleagues (2000). Briefly, images were converted to 
black and white, and the mean intensity value of each image measured (Adobe 
Photoshop). Standard error and student's t-test analysis were performed using 
SigmaStat (Jandel Scientific Software Corporation, San Rafael, CA). Using this 
method, it was possible to directly compare different treatment groups within an 
individual experiment using quantitative tools. However, it was not possible to 
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normalise intensity values between experiments performed in two or more different 
cultures (derived from separate fetuses). This is because the basal levels of MT-I/-II 
varied between different cultures, and immunocytochemistry and further analysis was 
not performed at the same time. In these cases, where results from different cultures 
were compared to each other, the overall changes in MT-I/-II expression (trendline) 
were qualitatively compared. 
To validate the use of mean MT-Ii-II intensity values as a means of observing 
changes in MT-I/-II expression at the immunocytochemical level, changes in MT-I/- 
II expression were observed following treatment of astrocyte cultures with zinc, a 
well known inducer of MT-U-II. Real-time PCR and western blotting results were 
similar to changes in mean MT-I/-II intensity values (Dittmann, 2002, BSc hons 
thesis), indicating that this is a suitable method for qualitatively observing changes in 
MT-I/-II expression. 
6.3 Results 
6.3.1 Changes in MT-I/-H expression following physical injury to astrocytes* 
* The work in 6.3.1 was performed by Justin Dittman (Dittman, 2002, BSc hons thesis), with 
supervision from the author. 
The simplest explanation for the up-regulation of MT following cortical 
injury is that astrocytes respond directly to physical trauma by inducing MT 
expression. To investigate this possibility, primary neonatal astrocyte cultures (21 
days in vitro) were mechanically injured, by performing scratch wound injuries using 
a microscalpel. Based on mean intensity values of MT-I/-II immunoreactivity, there 
was no change in MT-I/-II expression in response to physical injury, at up to 24 
hours post-injury (PI). This was observed directly adjacent to the injury tract, or at 
up to 200[tm from the scratch wound site (Figure 6.1). 
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Figure 6.1: Scratch wound injury in primary astrocyte cultures did not result in 
up-regulation of MT-I/-II at up to 24 hours post injury, either immediately 
bordering the injury site, or up to 2001.1m away. Taken from Dittmann, 2002, 
BSc hons thesis. 
6.3.2 MT-I/-11 immunoreactivity following scratch wound injury in 
neuron/astrocyte co-cultures 
To investigate a culture model that more closely resembles the environment 
of the brain, rat neuron/astrocyte co-cultures (21 days in vitro) were used. Although 
derived from E 18 rats, these cells are considered representative of those in the older 
brain, since they have matured in culture. Co-cultures were prepared as either 
neuron-.enriched (more than 50% neurons) or astrocyte-enriched (more than 50% 
astrocytes). Mechanical (scratch wound) injury was performed using a fine 
microscalpel, and changes in MT-I/-II expression evaluated by fluorescent 
immunocytochemistry. In un-injured co-cultures, MT-I/-II was detected at a basal 
level in some astrocytes (Figure 6.2A). MT-I/-II immunoreactivity was often 
nuclear, and not all astrocytes exhibited MT-I/-II immunoreactivity. Indeed, an MT 
positive astrocyte was often found beside an MT-I/-II negative astrocyte (Figure 
6.2A). 
At 1 hour post injury (PI), a number of MT-I/-II immunoreactive astrocytes 
were observed aligning along the scratch wound boundary (Figure 6.2B). MT-I/-II 
labelling was found not only within the nucleus, but also throughout the cell body, as 
well as astrocytic processes. Only astrocytes in close proximity to the scratch wound 
exhibited elevated labelling. 
By 6 hours PI, a number of broad, flat, fibrous astrocytic processes were 
observed entering the scratch wound area, which were both GFAP and MT-I/-II 
immunoreactive (Figure 6.2C). The distribution of astrocytes with elevated MT-I/-II 
levels beside the scratch wound was similar to that observed at 1 hour PI, although 
there appeared to be more of these cells at 6 hours PI. Many of the astrocytes within 
100um of the scratch wound exhibited increased MT-I/-II immunoreactivity (Figure 
6.2C). 
While levels of 	expression were not different in either neuron- or 
astrocyte- enriched co-cultures at up to 6 hours PI, differences in the response 
between the two culture models appeared by 24 hours PI. In neuron enriched co-
cultures (50% or more neurons), MT-I/-II immunoreactivity had significantly 
diminished by 24 hours PI, with few astrocytes exhibiting very low levels of MT-Y-II 
62 
.,
:s
 0
 0
 =
• 
0
 .
9
..
 e
, 
CT
' 	
6
1") 
a 
	a
.  
 
,
 
0
 	
L
..,
 . 	
.
 
■-1 
I-
I 	
Po
 
cra
 
CD
 • w
 "
C
i
P-r 
1
 
a 
-
1:,
'D 	
'i'D 
' 
0-'
.  o
cj ia
‘ 
2
1 
0
 C
I
'  
7
3
  
•
 
 
E.
 ...
..7
  
 
E.
  ''-
/
 g
 	
4
4
01 
 
5
 
a 
• ,
Y 
5 
5
. 
pp
 4
 g
- 
 
CA
 
..
.,
 • 
4 
0
  c
n
 
2 
c  
 s 
'0
 
n 
a 
9,
 5
; a
q 
7i
 
= .
 	
.4  C
)  d
e.
.  F
I  c
D
  5
,  
„
,
  
E
4
...•  
2,  ..._
.,  „„_  
,....___
_, 
a 
,ta
 <
 ,t
4.)
 
	
4.
 
'' 
' 	
,K
,--
 
a';,
 
,_.  -
.1
 -.
. 	
0 	
—
 ..
. 	
,-••  
q
  A
 	
■-t
 co 
, 5
-1
 
6 
(7
 0
 r
, 
_.
,-
 -
 -
 0
  .
 
- 
a.
 p
 	
(7
 .
..
 
	
Fp
' 
	
.....
.. 
 
'C
D
  
4
  p
o  a
3 
• 
g 	
0.•  
po
 
co
 ,
 	
= 	
,-■ 
=
 5
. 
0
 
o.
 <
 a
. 
r 4-
.  e
n" 
' 
• 
i 	
73
 C
L  
cyCD
  >
 C
D  
=
 c
-' 
• 
Cl'
-'
—
 
■-•
 ..
. •
 • 	
CD
 
-
 
=
 
C
A
 t
's
 	
CI
" I A
'
. 
I
 
 
o
>
 .
 	
; 
 
".
  ,
  —
 0
 0
 	
>
 c
o 
w
  '
-ri
 
cr, 
 
'CI
 
 
,--t 	
■-•
 
■-t.
 
■-i 
=
 
0
5
 
 
0 
= 
	8
 
0 
,_
„=.
 =
 
C
L• 
a. 
`-‹ 
	
, 
 
O
0
)o
l1
0
 -
4
.1
0
8
2
=
,_
,
0
w
‹,
.,
 
c)  
0
-  t
7
 8
 P
o 
6
 
 
(A
  ,,-
, 	
.  '
1:
1 
8 
0 
 •-
-4
 P
o  
,S
.,)  c
e,
 	
4 	
. 4
 
ocr
  H
 0
 	
0
cr.
  
CD
 
c4
  1
8
 '
-'
 .
 —
.F
' 
	
0
 P
o
 C
"
)  
C
T
 
.`-.
54
,...
. 
0-
 6
  R
-  g
 .
- 	
414
.
11)
 	
>
L
I  
1-
-t
eD
t-Z
CD
  
cr
 	
cD
- t
o
c
r■
E
=
=
 
T
 
FD
1 a
.' 
	
O 
FA
' 
.2
, 
2
. 2 
.1,, 
0
  _
 	
_ 
es•
 5
 
0 
.-t
-. 	
i-
t 
rt  -1  
0
-  =
 	
(,) 
Et
, 
2 
a
o
 
c
,c
a.
,
,
,'
' 	
0
0
t4
0
,.
.t
c
n
i-
",
--
:"
1
"`
•4
.  
p
 
A)
 	
0
 0
 
'i.")
 	
Po
g
 
 
cl 
C
D
 
5
 ■-.-1  i'i  
g .
...9
i 4
 	
g
.  
a.
 	
-
-
 •
 	
8
 0
 	
a
, 
L-  
c
e-.
),
 .
 5
  C
D=
  
. 
0
 —
• 
=
 —
 c
r,
 
r+
 	
,.. 
.../
 	
,4
. 
w
  0
 C
) 
Z
 0
 1
.4
 l
■
,  •
 (.
1
 	
p
 1
■
,  c
D
 
w
 5
 6
-J 
a
  C
D
 '=
', 
,—
, 
it
o 
 
labelling (Figure 6.2D). A number of astrocytic processes were observed entering, 
and in some cases crossing the injury site. The density of the astrocyte layer was 
reduced compared to previous time points. This was highlighted by a significant 
decrease in astrocytic process meshwork, which was replaced with thin, fragmented 
GFAP labelling (Figure 6.2D). Further, astrocytes appeared thin, spindly and 
filamentous. All astrocytes across the coverslip displayed increased GFAP 
immunoreactivity, throughout the cell body and processes. Astrocyte layers often 
detached from the coverslip, and were found floating in the medium. Furthermore, 
neurons exhibited punctate pIII-tubulin staining, indicating 'significant neuronal 
degeneration (results not shown). 
Contrastingly, in astrocyte enriched co-cultures (comprised of less than 50% 
neurons), MT-I/-II immunoreactivity had significantly increased by 24 hours PI, and 
was found in almost all astrocytes across the entire coverslip (Figure 6.2E). MT-I/-II 
staining was found throughout the cell body and fine processes, but was noticeably 
much lower and diffuse within the large, flat processes extending into the injury site. 
Measurements of the mean intensity of MT-I/-II immunoreactivity (Figure 
6.3) in neuron-rich cultures (more than 50% neurons) indicated a statistically 
significant, increasing trend from un-injured (average mean intensity value = 37.6 ± 
0.6) to 1 hour P1(52.0 ± 2; p<0.01, student's t-test) to 6 hours P1(70.2 ± 2.1; p<0.01, 
student's t-test). At 24 hours PI, MT-I/-II immunoreactivity had significantly 
decreased below the basal levels observed in un-injured cultures (22.5 ± 0.6; p<0.01, 
student's t-test). In cultures with less than 50% neurons, MT-I/-II immunoreactivity 
increased with time (Figure 6.3), from un-injured (24.1 ± 1.0), to 24 hours P1(96.6 ± 
2.4; p<0.01, student's t-test). 
6.3.3 Changes in un-injured cultures following addition of media from injured 
cultures* 
Based on the observation that only astrocytes co-cultured with neurons up-
regulate MT-I/-II expression in response to cellular injury, it was hypothesised that 
induction was neuron dependent. To investigate this hypothesis, a series of media 
* Astrocyte cultures were prepared by Justin Dittmann. 
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Figure 6.3: The mean intensity of MT-I/-II immunoreactivity surrounding the 
scratch wound site was measured at various time points post injury (PI). Un-
injured co-cultures exhibited a low basal expression of MT-I/-II. In neuron 
enriched co-cultures, scratch wound injury resulted in a significant increase in 
MT-I/-II intensity, increasing from 1 hour to 6 hours PI. By 24 hours PI, MT-I/-II 
levels had decreased to below basal, un-injured levels. In astrocyte enriched co-
cultures, MT-I/-II intensity increased with time. * - p < 0.001 compared to un-
injured, student's t-test. Similar intensity value patterns were observed in 
replicate experiments. Intensity values from the two different cultures (neuron-
rich and astrocyte-rich co-cultures) were not quantitatively comparable to each 
other because they were not processed for immunocytochemical analysis at the 
same time (see 6.2.1 for detailed explanation). 
exchange experiments were conducted. Briefly, culture medium from injured 
astrocyte, neuron and astrocyte/neuron co-cultures, all at 24 hours PI, was applied to 
un-injured co-cultures. Based upon changes in MT-I/-II immunoreactivity (Table 
6.1), only the culture medium from injured neuron cultures caused induction of MT-
I/-II expression. In further, preliminary experiments, culture medium was collected 
from injured astrocyte, neuron and neuron/astrocyte co-cultures (24 hours PI), and 
applied to un-injured astrocyte cultures. In all cases, there was no observable change 
in MT immunoreactivity after 24 hours (results not shown). 
6.3.4 Response of un-injured cultures to glutamate 
The requirement of a neuronal component for up regulation in MT-I/-II 
expression in astrocytes following injury suggests communication between injured 
neurons and surrounding astrocytes. One of the major communication systems 
between neurons and astrocytes is based upon glutamate signalling (for review, see 
Vesce et al., 1999). To investigate whether glutamate could be the potential 
mechanism responsible for the previous observations, un-injured neuron/astrocyte co-
cultures were treated with 1mM glutamate. This resulted in rapid MT-I/-II induction 
within astrocytes. Un-treated co-cultures exhibited no MT staining, or staining 
confined to the nucleus (Figure 6.4A). Within an hour of glutamate treatment, a 
number of astrocytes exhibited strong MT-I/-II staining, although not all astrocytes 
exhibited MT-I/-II immunoreactivity. Indeed, MT-I/-II immunoreactive astrocytes 
were often found next to non-immunoreactive astrocytes (Figure 6.4B). By 6 and 24 
hours post treatment, almost all astrocytes were strongly MT-I/-II immunoreactive, 
throughout the cytoplasm and associated processes (Figures 6.4C, D). Preliminary 
experiments performed by Justin Dittmann found that MT-I/-II expression in primary 
astrocyte cultures was unaltered by addition of 1mM glutamate (Dittmann, 2002, BSc 
hons thesis). 
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Injured culture 
media source 
Average MT 
Immunoreactivity value 
no media change 1 
injured astrocytes 0.96 ± 0.08 
injured neurons 2.13 ± 0.07* 
injured co-cultures 0.99 ± 0.13 
Table 6.1: Culture media from injured cultures (astrocytes, neurons and 
neuron/astrocyte co-cultures) were applied to un-injured co-cultures. The average 
MT immunoreactivity (as assessed by mean intensity values measured from 
digital images — see 6.2.1) was determined, and normalised to cultures from the 
same batch that had received no media change. Note that in this experiment, all 
immunocytochemical and subsequent processing was completed in the same run, 
so that intensity data could be compared between cultures. Only culture media 
from injured neuron cultures resulted in an increase in .MT immunoreactivity. * - 
p<0.01; student's t-test. Note: these experiments have been replicated in separate 
cultures derived from two pregnant rats. 
Figure 6.4: MT-I/-II (green) and GFAP (red) double-immunocytochemical 
analysis following 1mM glutamate treatment in neuron/astrocyte co-cultures. In 
un-treated cultures (A), MT-I/-II immunoreactivity was primarily nuclear. While 
all MT-I/-II immunoreactive cells were GFAP positive astrocytes, not all 
astrocytes were MT-I/-II immunoreactive. At 1 hour post-treatment (PT), a 
number of astrocytes exhibited strong MT staining (B), but not all astrocytes were 
MT immunoreactive. By 6 hours PT, almost all astrocytes were strongly MT 
immunoreactive (C), and this was similarly observed at 24 hours PT (D). Scale 
bars = 100um 
6.4 Discussion 
6.4.1 MT-I/I expression is upregulated in response to neuronal injury 
This chapter details the use of tissue culture models to investigate the possible 
mechanisms responsible for up-regulation of MT-I/-II expression following neuronal 
injury. Following scratch wound injury in these co-cultures, MT-I/-II was found in 
astrocytes aligned along the injury site. At later time points, almost all astrocytes 
within the culture were MT-I/-II immunoreactive. Induced MT-IJ-II was found both 
within the cell body and processes, while in un-injured controls, MT-I/-II staining 
was either absent or nuclear in localisation. These observations were analogous to 
those observed previously by Adlard (2000, PhD thesis) following focal cortical 
brain injury in live animals. Intriguingly, work performed concurrently to this thesis 
and presented in section 6.3.1 demonstrated that scratch wound injury in pure 
astrocyte cultures resulted in no change in MT-I/-II expression (Dittmann, 2002, BSc 
hons thesis). This suggests that MT induction was specifically elicited by neuronal 
injury, and that MT-I/-II plays an important role in the cellular response to neuronal 
injury. 
It was noted that there was a temporal difference in up-regulation in MT-I/-II 
expression in response to injury between the in vitro (within hours) and rat brain 
(within several days) injury models. This suggests that following cortical brain 
injury, a number of factors might act together in a complex manner to regulate MT 
expression in response to injury. 
6.4.2 The role of glutamate in MT-I/-H upregulation in response to neuronal 
injury 
Culture medium exchange experiments provided further evidence supporting 
the hypothesis that MT-I/-II is specifically up-regulated in response to neuronal 
injury. Un-injured co-cultures did not respond to culture media from injured 
astrocytes, but MT-I/-II expression was increased when medium from injured 
neurons was applied, suggesting that an extracellular factor released by neurons is 
responsible for MT-I/-II induction. Surprisingly, addition of culture media from 
injured co-cultures did not induce MT-I/-II expression. This suggests the possibility 
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that the astrocytes within the co-culture have removed the factor released by injured 
neurons. In a set of preliminary experiments, un-injured primary astrocyte cultures 
did not respond to any of the injured culture media, including that from injured 
neurons (results not shown). This suggests that astrocytes cultured in the absence of 
neurons are unable to respond to the trophic stimulus responsible for MT-I/-II 
induction. 
A possible explanation for the medium exchange experiments discussed 
above is that neurons rapidly communicate with neighbouring astrocytes via an 
extracellular signalling factor. It is well known that rapid cellular communication 
occurs between neurons and astrocytes based upon reciprocal glutamatergic 
signalling (for review, see Vesce et al, 1999). Indeed, the involvement of glutamate 
possibly explains the results observed in the media exchange experiments. 
Glutamate is released by neurons in response to injury, which would explain why 
medium from injured neurons causes MT-I/-II induction. The fact that media from 
injured co-cultures did not alter MT-I/-II expression could be due to astrocytic uptake 
of extracellular glutamate. Furthermore, the observation that astrocytes cultured in 
the absence of neurons do not respond to the stimulus (either media from injured 
neurons or 1 inM glutamate) could be because in the absence of neurons they exhibit 
very low levels of glutamate receptor expression (Schlag et al, 1998). As further 
confirmation of this hypothesis, experiments indicated that un-injured co-cultures 
rapidly respond to extracellular glutamate and up-regulate MT-I/-II in a similar 
temporal pattern to that observed following scratch wound injury. The fact that in 
neuron enriched co-cultures, scratch wound injury resulted in significant cellular 
death by 24 hours PI, suggests that the signalling mechanism is toxic at high 
concentrations, a known property of high extracellular levels of glutamate. To 
further elucidate the hypothesised role of glutamate in this system, culture medium 
could be analysed for glutamate content by HPLC. 
It has also been previously demonstrated that both MT-I/-II and MT-III 
transgenic knockout mice are highly susceptible to kainic acid induced seizures 
(Penkowa et al, 1999a; Erickson et al, 1997 respectively), while over expressing 
mice are protected from such treatment. Furthermore, Montoliu and colleagues 
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(2000) have recently demonstrated that exogenous MT-III is able to protect neurons 
from glutamate neurotoxicity (1mM). Based on the high structural similarity 
between MT-I/-II and MT-III, it seems possible that MT-I/-II exhibits similar 
protective properties. Combined with the numerous observations that MT-I/-II is 
significantly up-regulated following neuronal injury, this is suggestive that MT-I/-II 
is important in the brain's response to glutamate neurotoxicity caused by either 
neuronal injury or prolonged synaptic activity. 
Whilst the work here presents preliminary evidence suggesting glutamate as a 
putative mediator of the interaction between neurons and astrocytes, it should be 
noted that there are a large number of other possible candidates. Possibilities include 
other neurotransmitters, uncharacterised agents, neuronal components such as 
cytoskeletal elements. It should, however, be possible to use the model system 
established in this work to characterise the agent using standard biochemical and cell 
biological techniques. 
It is important to note that while advantageous in some respects, an important 
limitation of the culture models discussed in this chapter is the absence of immune 
cells. This means that the role of other agents capable of inducing MT expression, 
such as the proinflammatory cytokines IL-6 and TNF-a that are produced by immune 
cells, cannot be assessed within these experiments. In this regard, it is possible that a 
number of factors, including glutamate, zinc and cytokines, regulate MT expression 
in response to brain injury. However, differences both spatially and temporally in 
these factors might allow for quite precise, controlled regulation of MT expression. 
This would be in contrast to the prevailing thought that MTs are regulated as a 
generalised response to a variety of cellular stresses. Furthermore, it is possible that 
these factors regulate MT expression by different mechanisms (for instance, zinc acts 
through MT's metal responsive element while IL-6 induces MT expression through 
it's own Stat3 transcription factor), suggesting that some inducers may be able to 
over-ride other signals. 
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Chapter 7: Summary and concluding remarks 
7.1 Brief summary 
The aim of this thesis was to investigate possible extracellular actions of both 
major isoforms of MT found in the brain, MT-III and MT-I/-II. This research 
originated from the report more than 10 years ago by Uchida et al (1991), who 
identified MT-III as an inhibitor of neuronal survival. They also proposed that MT-
III inhibited neurite sprouting, although no detailed quantitative assessment of this 
property was initially presented. This thesis describes a detailed quantitative analysis 
of this proposed property of MT-III, and indicates that human MT-III inhibits initial 
neurite formation and outgrowth in cultured cortical neurons. Rather surprisingly, 
while human MT-IIA did not affect initial neurite formation, it was found to 
significantly promote neurite elongation. Based on these findings, the importance of 
these properties under physiological conditions and within several models of 
neuronal injury were examined. Both MT-III and MT-IA exhibited these 
neuroactive properties in an in vitro model of neuronal injury and regeneration 
(cluster neuron cultures). However, it was found that exogenously applied MT-III 
and MT-IIA elicit a variety of responses following axonal transection in culture. For 
instance, MT-III inhibited reactive neurite sprouting and growth, while MT-IIA 
increased reactive sprouting and growth. These results are relevant from an 
experimental point of view, but they also indicate the possibility that we have 
revealed an actual, and previously unsuspected, component of the physiological role 
for these proteins. Furthermore, they may lead to further work to explore the 
possibility of therapeutic action, especially for MT-IIA. 
7.2 MTs exhibit isoform specific neuroactive properties 
An intriguing feature of the MT family of proteins is the existence of multiple 
isoforms in mammals. It has been hypothesised that the various MT isoforms 
provide functional diversity, but some MT literature does not support this. For 
instance, all MT isoforms exhibit heavy metal binding activity and the ability to 
scavenge free radicals (as reviewed by Aschner et al, 1997). However, the work 
reported in this thesis indicates that human MT-IIA (the major representative at the 
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protein level of the human MT-I and MT-II isoforms) and MT-III exhibit remarkably 
opposing extracellular, neuroactive properties. Human MT-IIA and MT-III share a 
70% sequence homology, and also exhibit similar metal binding properties. Indeed, 
the 20 conserved cysteine residues, which characterise the mammalian MTs, are 
conserved within these isoforms (with the notable exception of sheep MT-III, 
discussed in this thesis). Interestingly, Sewell et al (1995) found that by changing the 
C(6 )PCP motif of MT-III to the C(6)SCT motif found in MT-I/-II isoforms, MT-III's 
ability to inhibit neuronal survival was abolished. Likewise, engineering of the 
T(5)CPCP motif found in MT-III into the MT-I sequence resulted in neurotoxic 
activity (Romero-Isart et al, 2002). This indicates that relatively small changes in 
protein structure result in quite marked biological differences within these proteins. 
The opposing neuroactive properties of these remarkably similar MT isoforms, 
combined with their specific spatial and temporal expression patterns following 
injury, suggests that the neuroactive properties of MTs are specialised, true 
physiological functions of these proteins. As a further indication of this, the C (6)PCP 
motif, which confers MT-III its inhibitory effect upon neuronal survival, is conserved 
throughout all mammalian MT-Ins identified to date, including the unusual sheep 
MT-III described in Chapter 3. 
7.3 Elucidation of a potential physiological role of MTs within the brain 
It is following neuronal injury that the neuroactive properties of MTs appear 
most important. Indeed, the work presented in this thesis, together with substantial 
MT literature, suggests a novel physiological role for MTs within the brain following 
injury. Clearly, neuronal injury results in significantly increased expression of MT 
within astrocytes (based on work presented in this thesis, this could be due to a 
number of different factors such as cytokines, zinc and glutamate), both within the rat 
brain and in culture. While it has not been well explored, there is evidence to suggest 
that under certain physiological conditions, astrocytes release MT into the 
extracellular environment. This released MT could then exhibit its extracellular 
functions including suppression of inflammatory response, protection from apoptosis 
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or direct neuroactive effects (such as neuroprotection and enhancing neuronal 
regeneration)(see Figure 7.1). 
While it is possible to postulate that within the brain, MTs play an important 
role in the cellular response to neuronal injury, investigation of the extracellular 
release of MT is crucial to elucidation of this idea. While there is evidence to suggest 
that cultured astrocytes release MT into medium (Uchida et al, 2002), the mechanism 
involved is not known. For example, MTs do not possess known signal sequences or 
other motifs associated with release into the extracellular environment (Palmiter et al, 
1992). MT-I/-II was observed in gel foam following cortical brain injury, in the 
apparent absence of astrocytes and microglia, indicating that this MT-I/-II is a 
component of the extracellular fluid (Chapter 5). MT-I/-II was detected at both 7 and 
14 days post-injury, in parallel to the astrocytic up-regulation of MT-I/-II 
surrounding the injury tract. However, this detection method is rather crude. 
Microdialysis techniques have been applied to monitor the changes in the 
extracellular brain environment, including changes in extracellular glutamate, lactate 
and neurotrophic factors (Di et al, 1999; Mendelowitsch et al, 2001; Humpel et al, 
1995 respectively). Such techniques could be readily adapted to accurately measure 
the changes in MT levels within extracellular brain fluid in response to brain injury. 
It must be noted that the prevailing dogma is that MTs are intracellular proteins, 
which have functional roles inside the cell (Palmiter et al, 1992). However, the work 
described in this thesis indicates that MTs also have extracellular functions. Further 
investigation of the release and activity of extracellular MT in physiological 
conditions may reveal the elusive function of these proteins. 
7.4 MTs — a potential family of neurotrophic factors within the brain 
It is over half a century since the discovery of the first peptide growth factor, 
nerve growth factor (NGF). Indeed, NGF has become the model neurotrophic factor 
(a factor which can regulate neuronal death, survival, growth and differentiation; as 
discussed by Barde, 1989). While this classical definition still holds true, it has been 
extended to reflect that neurotrophic factors may exhibit multiple effects, as well as 
having distinct functions at different times during development and following 
70 
Figure 7.1: A diagrammatic model describing a possible physiological role of 
extracellular MT within the brain. Astrocytes are closely associated with neurons 
within the CNS (A). Chemical or physical injury to the axon (B) is detected by 
astrocytes, perhaps by a diffusible factor or by direct cell-to-cell contact,  for example 
in the vicinity of the synapse (circle). This induces MT production concurrent with 
axonal degeneration (C), leading to increased extracellular levels  of MT, thus 
promoting axonal sprouting (D). Thanks to Dr Adrian West for designing the above 
figure. 
neuronal injury (Unsicker et al, 1992). According to this definition, MTs could be 
considered as a family of neurotrophic factors. Indeed, MTs exhibit neuronal death, 
survival and growth regulating actions, as demonstrated both in culture and within 
the brain. The different neuroactive properties of various MT isoforms is not 
uncommon within families of neurotrophic factors. For instance, the epidermal 
growth factor family, the glial derived neurotrophic factor family and the related 
neuregulin family of neurotrophic factors contain a number of isoforms which exhibit 
differing functional properties within the nervous system, such as enhancing survival 
and inhibiting apoptosis of post-mitotic neurons, and promoting proliferation, 
migration and differentiation of neuronal precursors (for review, see Xian & Zhou, 
1999). 
7.5 Therapeutic potential of MTs 
Within this thesis, the ability of MT-I/-II (namely human MT-IA) to 
modulate CNS injury has been examined following cortical needle stick injury to the 
rat brain. The rat cortical brain injury model used in this study results in a sequence 
of cytoskeletal changes which are similar to the reactive changes observed in both 
human and experimental brain injury studies (Maxwell et al, 1997). Hence, human 
MT-IA may be a valuable therapeutic agent in treating human brain injuries. 
Furthermore, research by Juan Hidalgo and associates indicates that MT treatment 
can also alleviate the symptoms of EAE in rats, an animal model of multiple sclerosis 
(Penkowa & Hidalgo, 2000; 2001). This suggests that MT-IA could potentially be 
used for the treatment of a broad range of CNS injuries or neurodegenerative diseases 
(see Table 7.1). Examination of the efficacy of MT-IA treatment in other animals 
models of both CNS injury (such as spinal cord injury) and neurodegenerative 
diseases (such as P-amyloid transgenic mice) will provide significant insight into the 
therapeutic potential of MTs. 
In contrast to situations following neuronal injury that result .in a lack of 
neural regeneration, there are also neurodegenerative conditions that result in 
excessive and aberrant neurite sprouting. These include AD (as evidenced by 
neurofibrillary tangle formation) and seizure related disorders such as epilepsy and 
71 
Disease Indication Role of MTI/II (IA) 
Alzheimer's 
disease 
Promote neuronal survival and 
regeneration. 
Buffer metals implicated in 
development of pathological 
hallmarks. 
Our lab has demonstrated 
that MTI/II is upregulated 
in early stages of the 
disease (Adlard et al, 
1998) 
Parkinson's 
disease 
Promote neuronal survival and 
regeneration. 
Buffer metals implicated in 
toxicity. 
Evidence of abnormal 
metal homeostasis in the 
brain, as well as 
neurodegeneration. 
Motor neuron 
disease 
Promote nerve cell survival. 
Promote neuronal regeneration. 
Buffer metals implicated in 
toxicity. 
Reduce oxidative stress implicated 
in neuronal degeneration. 
Evidence of abnormal 
metal homeostasis in the 
brain and spinal cord as 
well as neurodegeneration. 
Head injury Promote nerve cell survival. 
Promote neuronal regeneration. 
• 
It has been shown that MT 
1./II is upregulated at zone 
of injury (Adlard, 2000). 
Recombinant protein 
promotes brain healing 
and axonal regeneration 
(Chapter 5) 
Spinal cord 
trauma 
Promote nerve cell survival. 
Promote neuronal regeneration. 
, 
Evidence of delayed 
neurodegeneration and 
spinal cavitation following 
injury. Chapter 5 indicates 
that the recombinant 
protein is capable of 
promoting neural healing 
and regeneration. 
Glaucoma Promote nerve cell survival. 
Promote neuronal regeneration. 
Axonal damage followed 
by neurodegeneration 
underlies the disease. 
MTI/II may potentially 
promote survival of nerve 
cells and/or appropriate 
regeneration. 
Table 7.1: Neurodegenerative diseases which could potentially be treated with 
human MT-IA. Note that this is not an exhaustive list, but is designed to indicate 
the range of conditions which could potentially be treated with MT-IA. 
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schizophrenia. It is possible to envisage that the neurite inhibitory properties of MT-
III may be utilised as a therapeutic agent to treat these conditions. Furthermore, the 
opposing effects of MT-III and MT-IA indicate that treatment could involve a 
combination of these isoforms. For example, MT-III could be used to initially 
prevent reactive neurite sprouting following injury, allowing time for the modulation 
of the injury environment, at which point MT-IA could be applied to promote 
regenerative neurite growth. 
MTs possess a number of generic properties which promote their possible use 
as a therapeutic agent. Unlike chemical based treatments for neuronal injury, MT is a 
naturally occurring protein found in the human brain. Further, MT (as a zinc-
thionein) is known to be non-toxic in the doses used within this thesis (Suzuki et al, 
1979). MT following intraperitineol application has also been shown to rapidly enter 
the CNS in certain experimental situations (Penkowa & Hidalgo, 2001), indicating a 
possible therapeutic route for MT-.- 
The therapeutic potential of MTs, while extremely exciting, requires further 
investigation. For instance, it will be important to determine the relative contribution 
of MT's direct action upon injured neurons in vivo with its previously established 
ability to suppress CNS inflammatory response following injury. This could be 
elucidated by examining MT action in immunosuppressed rats (by the use of 
cyclosporin A), or in nude mice (mice lacking a functional immune system). 
Furthermore, there are critical functional regions of the MT molecule, which are 
responsible for its neuroactive activity. Definition of these regions (such as the 
C(6)PCP motif of MT-III responsible for neurotoxicity) will allow the design of active 
peptide analogues of MT with enhanced neuroactivity, which may be suitable for 
therapeutic use. 
Because MT over-expressing mice exhibit increased tolerance to cortical 
brain injury (Campagne et al, 2000; Giralt et al, 2002) and chemically induced 
seizures (Erickson et al, 1997; Giralt et al, 2002), it is possible to envisage the use of 
MTs as a preventative treatment. Perhaps in the future, MT supplementation may 
protect people from CNS damage caused by a variety of insults (such as oxidative 
stress) or neurodegenerative disorders (such as AD). As an indication of this, 
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Hidalgo and co-workers have used intra-peritoneal injections of Zn-MT-II (Sigma) to 
ameliorate the neurological damage which occurs during EAE, a rat model of 
multiple sclerosis (Penkowa & Hidalgo, 2000, 2001). 
Alternatively, the work described within this thesis presents the hypothesis 
that MTs have an important intrinsic role in promoting cortical wound healing. This 
suggests that less invasive enhancement of this protective mechanism could be 
considered as a therapeutic treatment. While the literature discusses a number of 
inducers of MT expression, such agents (including zinc, cytokines such as IL-1 and 
IL-6) have multiple effects within the brain. In this regard, the identification of a 
• specific inducer of MT expression could provide an avenue to enhance the 
endogenous protective role of MT within the brain. 
7.6 Conclusion 
This thesis presents evidence indicating that MT-I/-II and MT-III possess 
remarkably different properties when applied to several culture and in vivo models of 
neuronal damage. Furthermore, the changes in their expression following brain 
injury and in some neurological disorders, in combination with these neurotrophic 
properties, suggest that these proteins have an important physiological role within the 
cellular response to neuronal injury. Based upon their neurotrophic properties, MTs 
also have therapeutic potential for the possible treatment of a broad range of CNS 
injuries and neurodegenerative diseases. 
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